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a b s t r a c t
Since the discovery of glucocorticoids in the 1940s and the recognition of their anti-inﬂammatory effects,
they have been amongst the most widely used and effective treatments to control inﬂammatory and
autoimmune diseases. However, their clinical efﬁcacy is compromised by the metabolic effects of long-
term treatment, which include osteoporosis, hypertension, dyslipidaemia and insulin resistance/type 2eywords:
lucocorticoid
nﬂammation
1-Hydroxysteroid dehydrogenase
diabetes mellitus. In recent years, a great deal of effort has been invested in identifying compounds that
separate the beneﬁcial anti-inﬂammatory effects from the adverse metabolic effects of glucocorticoids,
with limited effect. It is clear that for these efforts to be effective, a greater understanding is required of
themechanismsbywhichglucocorticoidsexert their anti-inﬂammatoryand immunosuppressiveactions.
Recent research is shedding new light on some of these mechanisms and has produced some surprising
new ﬁndings. Some of these recent developments are reviewed here.
© 2010 Elsevier Ireland Ltd. All rights reserved.
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. Introduction
Natural and synthetic glucocorticoids remain at the forefront
ment of certain leukaemias and in immunosuppressive regimes
following organ transplant. At any one time, an estimated ∼1%
of the total adult population of the UK receives oral glucocor-f anti-inﬂammatory and immunosuppressive therapies. They are
idely used to treat both acute and chronic inﬂammations, includ-
ng rheumatoid arthritis, inﬂammatory bowel disease, multiple
clerosis, psoriasis and eczema, as well as being used in treat-
∗ Corresponding author. Tel.: +44 131 242 6736; fax: +44 131 242 6779.
E-mail address: Karen.Chapman@ed.ac.uk (K.E. Chapman).
303-7207/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.
oi:10.1016/j.mce.2010.04.005ticoid therapy (van Staa et al., 2000). However, long-term use
of oral glucocorticoids is associated with serious side effects,
including osteoporosis, metabolic disease and increased risk of
cardiovascular disease (Wei et al., 2004; Souverein et al., 2004;
de Vries et al., 2007; Vegiopoulos and Herzig, 2007)—in them-
selves, somewhat paradoxically, inﬂammatory conditions. Over the
60 years since the discovery of glucocorticoids, much has been
learnt of the molecular mechanisms by which they act (recently
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eviewed; Perretti and Ahluwalia (2000), Necela and Cidlowski
2004), Yeager et al. (2004), Rhen and Cidlowski (2005), Smoak
nd Cidlowski (2004), Tuckermann et al. (2005), Kleiman and
uckermann (2007), Newton and Holden (2007) and De Bosscher
nd Haegeman (2009)), with milestones being the characterisation
f the glucocorticoid receptor (GR) as a DNA binding protein that
egulates transcription initiation (reviewed, Yamamoto (1985)),
he cloning of GR (Hollenberg et al., 1985; Miesfeld et al., 1986) and
he discovery that many of the immunosuppressive actions of glu-
ocorticoids aremediatedby interferencewith signallingby thekey
nﬂammatory transcriptional regulators; NF-B and AP-1 (Jonat et
l., 1990; Yangyen et al., 1990; Heck et al., 1994) (reviewed, McKay
nd Cidlowski (1999)). However, much also remains unknown and
he past few years have provided crucial mechanistic insights into
he dynamic nature of GR interactions with DNA and higher order
hromatin structures, into the subtleties of ligand effects on GR
unction, the regulation of endogenous ligand access to GR, gluco-
orticoid effects on leukocyte differentiation and function and the
echanistic basis for some of the repressive actions of glucocorti-
oids, critical for their anti-inﬂammatory effects.
. Inﬂammation and its resolution
The host inﬂammatory response is a primary defence
echanism engaged immediately following injury or infection
hich is necessary to restore homeostasis following success-
ul elimination of the injurious agent, ultimately leading to
esolution and tissue repair. Although categorically distinct,
he innate (the relatively non-speciﬁc immediate host defence
ystem that provides a rapid reaction to infection and tis-
ue damage) and adaptive (the more slowly acquired, highly
ntigen-speciﬁc response) immune systems interact and often
verlap during an inﬂammatory response. Indeed, although acute
nﬂammation is largely mediated by the innate immune sys-
em, the adaptive immune system often plays a major role
n chronic inﬂammatory disease, with dysregulated lymphocyte
esponses.
Inﬂammation is initiated at the site of injury by resident cells,
articularly mast cells and resident macrophages, which release
ro-inﬂammatory mediators including bioactive amines, lipid
ediators and cytokines—typically TNF- and IL-1. These cause
asodilation, increased capillary permeability (humoral response)
nd leukocyte emigration into injured tissues (cellular response),
esulting in the hallmark pain, heat, redness and swelling of inﬂam-
ation as well as generating a chemotactic gradient to guide
nd activate recruited cells to the site of injury. Although speciﬁc
haracteristics depend on the immune exposure (e.g. irritant vs
athogen), the recruitment process and activation of inﬂammatory
ells are common. Activated granulocytes, crucial to containmicro-
ial infection, are rapidly attracted to the inﬂamed site, followed
y monocyte emigration from blood vessels and subsequent mat-
ration into macrophages. Once at the inﬂamed site, neutrophils
ndergo constitutive apoptosis, functionally isolating them from
he inﬂammatory environment by loss of stimulated chemotaxis,
hagocytosis, degranulation and respiratory burst (Haslett et al.,
991; Whyte et al., 1993), whilst at the same time, facilitating safe
emoval of their potentially histotoxic contents by macrophages
Savill et al., 2002). Foreign antigens are taken up by antigen pre-
enting cells; particularly dendritic cells, but also macrophages,
hat then migrate to draining lymph nodes where they instruct
he adaptive immune system (T and B lymphocytes), shaping the
ubsequent immune response. As the inﬂammatory response pro-
resses andevolves,mononuclear cells predominate and resolution
ormally ensues. Successful resolution of acute inﬂammation is an
ctive and highly regulated process and dependent onmechanismsellular Endocrinology 335 (2011) 2–13 3
engaged early in the inﬂammatory response that programme the
trajectory and formof the subsequent resolution (reviewedSavill et
al. (2002), Gilroy (2004) and Serhan and Savill (2005)). Persistence
of the initiating stimulus invariably leads to chronic inﬂammation,
with the typical dysregulation between destructive inﬂammatory
and excessive healing responses seen in diseases such as arthritis,
atherosclerosis and asthma.
3. Glucocorticoids and inﬂammation
Glucocorticoids inhibit many of the initial events in an inﬂam-
matory response. Theyalsopromote the resolutionof inﬂammation
although the mechanisms by which they do so have received
less attention than those associated with suppression of the
initial response. Acutely, glucocorticoids inhibit the vasodila-
tion and increased vascular permeability that occurs following
inﬂammatory insult and they decrease leukocyte emigration into
inﬂamed sites, effects that require newprotein synthesis (reviewed
Perretti and Ahluwalia (2000)). They also alter leukocyte distribu-
tion/trafﬁcking (McEwen et al., 1997), death/survival (McEwen et
al., 1997; Ashwell et al., 2000; Planey and Litwack, 2000; Herold et
al., 2006; McColl et al., 2007) and, importantly, alter cellular differ-
entiation programmes, thus shaping the subsequent response (see
below).
Most of the anti-inﬂammatory and immunosuppressive actions
of glucocorticoids are attributable eitherdirectly or indirectly to the
transcriptional effects of GR agonism which alters transcription of
numerous genes in leukocytes, both up and down (Ashwell et al.,
2000; McEwen et al., 1997). Although expression of mineralocorti-
coid receptor (MR), which binds glucocorticoids with high afﬁnity
in the absence of 11-hydroxysteroid dehydrogenase type 2 (11-
HSD2; see below), has been reported in immune cells (Miller et
al., 1990; Barish et al., 2005; Lim et al., 2007) (which do not nor-
mally express 11-HSD2 Gilmour et al. (2006), Lim et al. (2007)),
it appears of little consequence to the anti-inﬂammatory effects of
glucocorticoids, and may even have pro-inﬂammatory effects (Lim
et al., 2007; Harizi et al., 2008). It should also be noted that some
anti-inﬂammatory effects of glucocorticoids are apparent within
minutes and a number are independent of the transcriptional
effects of GR (see for example Croxtall et al. (2002), Limbourg et al.
(2002) and Stellato (2004)). Notably, glucocorticoids repress tran-
scription of many genes encoding pro-inﬂammatory cytokines and
chemokines, cell adhesion molecules and key enzymes involved
in the initiation and/or maintenance of the host inﬂammatory
response (reviewed Barnes (1998), Perretti and Ahluwalia (2000)
and Smoak and Cidlowski (2004)). Many of these genes are com-
monly over-expressed during chronic non-resolving inﬂammation.
Intriguingly, recent data have shown that whereas glucocorticoid
administration 1h following endotoxin (lipopolysaccharide, LPS)
challenge is immunosuppressive, administration of the same glu-
cocorticoiddoseprior to LPS challengeaugments immune responses
(Franket al., 2010). Thiswas true inboth thebrainand the liver, rais-
ing the possibility that chronic hypothalamic–pituitary–adrenal
(HPA) axis activation (as may occur during chronic inﬂammation
for example) exaccerbates inﬂammation in thebrain andelsewhere
(reviewed in Sorrells et al. (2009)).
Until recently, it was widely believed that the repressive, anti-
inﬂammatory effects of glucocorticoids were dependent on the
ability of GR to inhibit the activity of crucial transcriptional reg-
ulators of pro-inﬂammatory genes, including NF-B and AP-1, by
a mechanism termed “transrepression”. This contrasted with the
metabolic actions of glucocorticoids which require gene activation
by GR. This view has recently been revised, with the discovery that
key anti-inﬂammatory actions of glucocorticoids are brought about
through gene activation (Clark, 2007) (and see below).
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. The repressive actions of glucocorticoids
The ability of GR to repress the activity of NF-B and AP-1 as
ell as other key immunomodulatory transcription factors has
een a major focus of research into the mechanisms underlying
he anti-inﬂammatory effects of glucocorticoids. Although a role
or transactivation by GR in repression of NF-B was implicated
inducing expression of the NF-B inhibitor, IB (Auphan et
l., 1995; Scheinman et al., 1995) – this was restricted to cer-
ain cell types and did not appear to be a universal mechanism
Heck et al., 1997; Wissink et al., 1998). Biochemical and genetic
vidence suggested that negative regulation by a transrepression
or “tethering”) mechanism independent of DNA binding by GR
nderpinned the repressive effects of glucocorticoids (reviewed
moak and Cidlowski (2004) and Clark (2007)) and this, by exten-
ion, was thought to be responsible for their clinical efﬁcacy.
n contrast to gene activation by GR, which at the time was
elieved to occur exclusively through homodimers of GR bind-
ng to palindromic glucocorticoid response elements (GREs) (Beato
t al., 1996; Karin, 1998), transrepression involves direct protein-
roteinbindingofGR toother transcription factors and interference
ith their mechanism of action. The interaction requires the DNA
inding domain of GR (but not DNA binding per se) and does
ot require conventional homodimerisation of GR (Barnes, 1998;
arin, 1998; Smoak and Cidlowski, 2004). Transrepression was
ot affected by mutation of alanine 458 to threonine (A458T)
ithin the dimerisation interface of the DNA binding domain that
ramatically reduces GR transactivation of the MMTV-LTR pro-
oter and the tyrosine aminotransferase (TAT) gene promoter,
oth classically activated by GR through well-characterised palin-
romic GREs (Payvar et al., 1983; Grange et al., 1989). Considerable
upport for the transrepressionhypothesis came from in vivoexper-
ments in mice in which the wild-type GR was replaced by the
imerisation (dim) mutant (GRdim mice) (Reichardt et al., 1998).
lucocorticoid-mediated repression of AP-1-dependent transcrip-
ion and other pro-inﬂammatory genes was intact in these mice, in
ontrast to defective GRE-dependent transactivation (Reichardt et
l., 1998, 2001). However, transactivation of some genes, including
hat encoding phenylethanolamine N-methyltrasferase (PNMT),
emained intact (Reichardt et al., 1998). It has since emerged
hat the GRE in the PNMT gene belongs to a different class of
RE to the palindromic consensus, and comprises a series of
epeated half sites to which GR directly binds to activate tran-
cription from the PNMT promoter (Adams et al., 2003). Dual
peciﬁcity phosphatase (DUSP) 1, also known as MKP-1 (mitogen
ctivated protein kinase [MAPK] phosphatase 1), a crucial anti-
nﬂammatory gene (Hammer et al., 2006; Salojin et al., 2006; Zhao
t al., 2006; Maier et al., 2007), also remains fully inducible in
Rdim mice (Abraham et al., 2006), offering an alternative inter-
retation of their phenotype. Glucocorticoid induction of DUSP1
ay have some similarity to that of PNMT, as recent work has
hown the glucocorticoid responsive region in the DUSP1 gene
ontains 3 closely spaced half sites (Tchen et al., 2009), although
tethering mechanism of activation dependent on C/EBP has
lso been implicated (Johansson Haque et al., 2008). Thus, at
east some, but not all, of the dimerisation-independent repres-
ive actions of glucocorticoids may be wholly or partly dependent
n induction of DUSP1. Consistent with this, glucocorticoids failed
o suppress zymosan-induced inﬂammation in DUSP1−/− mice,
hereas inﬂammation was suppressed in control mice (Abraham
t al., 2006). However, DUSP1−/− mice remain sensitive to the
uppressive effects of glucocorticoids in mast cell-dependent ana-
hylaxis (Maier et al., 2007), implicating other mechanisms in the
nti-inﬂammatory actionof glucocorticoids in thismodel of inﬂam-
ation. Intriguingly, DUSP1−/− mice are resistant to diet-induced
besity (Wu et al., 2006), raising the possibility that DUSP1 mayellular Endocrinology 335 (2011) 2–13
also be involved in some of the metabolic effects of glucocorti-
coids.
The anti-inﬂammatory actions of glucocorticoid-induced genes
have been recently reviewed (Clark, 2007). Brieﬂy, as well as
DUSP1 and IB, this class of genes includes IL-10, a potent
immunomodulatory and anti-inﬂammatory cytokine (Couper et
al., 2008), Glucocorticoid-induced leucine zipper (GILZ), a pro-
tein whose mechanism of action is unclear but which interacts
with, and inhibits the function of, NFB and AP-1 (Ayroldi and
Riccardi, 2009) and annexin AI (AnxA1), a calcium-dependent
phospholipid binding protein (Perretti and D’Acquisto, 2009). GILZ
knockout mice have not been reported, but AnxA1-deﬁcient mice
show defective glucocorticoid suppression of inﬂammation in
carrageenin-induced oedema, zymosan-induced peritonitis and
antigen-induced arthritis (Hannon et al., 2003; Yang et al., 2004).
IL-10-deﬁcient mice develop autoimmune disease and chronic
inﬂammation (Kuhn et al., 1993; Rennick et al., 1995), but effects
of glucocorticoids in these mice have not been reported. However,
IL-10 has been implicated in negative regulation of corticosterone
synthesis, acting at the adrenal gland (Koldzic-Zivanovic et al.,
2006), providing a plausible homeostatic mechanism to termi-
nate HPA axis activation once inﬂammation is resolving. Like IL-10,
administration of AnxA1 can mimic a subset of the effects of glu-
cocorticoids (although in T cells, AnxA1 effects may be opposite to
those of glucocorticoids) (Perretti and D’Acquisto, 2009). Similarly,
ectopic expression of GILZ in T cells (Delﬁno et al., 2006; Cannarile
et al., 2006, 2009) and dendritic cells (Cohen et al., 2006) canmimic
some of the effects of glucocorticoid. Indeed, some of the effects of
both IL-10 and AnxA1 may even be mediated by GILZ (Cannarile et
al., 2009; Yang et al., 2009a), although as IL-10, AnxaA1 and GILZ
all alter differentiation or activation state of immune cells (Yona et
al., 2004; Cohen et al., 2006; D’Acquisto et al., 2007a,b; Couper et
al., 2008; Huggins et al., 2009), such conclusions remain tentative.
Glucocorticoids induce GILZ in a variety of cell types, both
immuneandnon-immune (Clark, 2007), throughpalindromicGREs
in the 5′-ﬂanking region of the GILZ gene (Wang et al., 2004; van
der Laan et al., 2008), dependent on dimerisation of GR (Rogatsky
et al., 2003). How they regulate IL-10 and AnxA1 remains unclear.
In vitro, glucocorticoids increase IL-10 expression in monocytes
(Mozo et al., 2004), macrophages (Ehrchen et al., 2007) and, depen-
dent onantigenpresenting cells, in T cells (Richards et al., 2000), but
whether this is related to glucocorticoid-driven alterations in cellu-
lar differentiation (see below) or whether glucocorticoid-induced
IL-10 indeed mediates some of the effects of glucocorticoids on dif-
ferentiation as suggested (Richards et al., 2000) remains unknown.
Glucocorticoids increase AnxA1 expression on human monocytes
and neutrophils in vivo (Goulding et al., 1990) and in pituitary
folliculostellate cells in vitro (Solito et al., 2003) and whilst the
underlying mechanisms remain unclear, they appear to involve
both non-genomic and genomic actions of glucocorticoids, the lat-
ter both modest and relatively slow (Solito et al., 2003). Moreover,
glucocorticoids decrease AnxA1 mRNA in T cells (D’Acquisto et
al., 2008), raising the possibility that glucocorticoid regulation in
adaptive and innate immune cells may be related to differentia-
tion/activation state rather than being a direct regulation.
5. Context-speciﬁc gene regulation by GR
Transcriptional repression by GR has always been the subject
of debate, as alluded to above, including the extent to which it
is dependent or independent of direct GR DNA binding. How-
ever, it is agreed that gene activation requires DNA binding by
GR. Much of the early work on GR transcriptional activation was
based around a consensus GR binding site, comprising two 6bp
“half sites” arranged in an inverted repeat (palindrome) sepa-
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ated by a 3bp spacer, derived from comparisons of around 20
R binding sites in promoters including the MMTV-LTR (Beato
t al., 1989; Umesono and Evans, 1989). Subsequent work has
onﬁrmed this (Reddy et al., 2009) but additionally shown GR-
ediated gene regulation to be much more complex (reviewed
n detail in Lefstin and Yamamoto (1998), Grange et al. (2001),
ager et al. (2004), Clark (2007) and Biddie and Hager (2009)).
recent unbiased screen of GR binding sites coupled with tran-
criptome analysis showed that genes activated by glucocorticoid
ad GR bound within a median distance of 11kb from the tran-
cription start site whereas repressed genes had GR bound a
edian of 146kb from the transcription start site, suggesting that
epression occurs independently of promoter-proximal GR bind-
ng (Reddy et al., 2009). In silico prediction, genome scanning,
hemically directed sequence-speciﬁc disruption of GR binding
nd chromatin immunoprecipitation experiments have shown that
equences that match the GR consensus do not necessarily bind GR
n cells (Horie-Inoue et al., 2006; So et al., 2008) and that disruption
f GR binding to the conserved half site sequence 5′-WGWWCW-3′
where W=A/T) only affects a minority of glucocorticoid-regulated
enes, both repressed and activated (Muzikar et al., 2009). It has
ong been clear that many GR binding sites (core sites) are embed-
ed in “composite” glucocorticoid responsive units (e.g. Imai et
l. (1990), Alam et al. (1993) and Beato et al. (1996)). Core GR
inding sites vary considerably around the consensus (Wang et
l., 2004; So et al., 2007) although the precise sequence in and
mmediately around the core GR binding site in a gene (the glu-
ocorticoid responsive unit) is highly conserved between species
So et al., 2007). Moreover, actual occupancy by GR is inﬂuenced
y post-translational modiﬁcation (Blind and Garabedian, 2008)
nd depends on cell-speciﬁc factors (So et al., 2007). Thus, efﬁ-
ient glucocorticoid regulation depends on concomitant binding
y other transcription factors at composite elements, to the extent
hat GR may “tether” at some promoters, retained principally by
rotein–protein interactions rather than direct interactions with
NA (Lefstin and Yamamoto, 1998). Given that GR homodimerisa-
ion, at least of the isolated DNA binding domain, only occurs on
NA binding (Härd et al., 1990; Luisi et al., 1991), then monomers
f GR may bind to divergent sequences at composite response ele-
ents or by tethering to other transcription factors (Lefstin and
amamoto, 1998). Thus, the context of the GR binding site is crucial
ith the outcome– repression, activation or even speciﬁcity (MR vs
R) – dependent on the cell-speciﬁc complement of transcription
actors (Grangeet al., 1991;YoshinagaandYamamoto, 1991;Pearce
nd Yamamoto, 1993). Whether and how GR contacts DNA might
e critical. The GR DNA binding sequence itself acts as an allosteric
egulator of GR function, dictating the pattern of regulation that
nsues following GR binding (Lefstin and Yamamoto, 1998; van
ilborg et al., 2000; Meijsing et al., 2009). DNA binding induces
onformational changes in the dimerisation interface that expose
therwise silent transcriptional activation surfaces (van Tilborg et
l., 2000). These conformational changes are exquisitely sensitive
o theDNAsequence,with single basepair differences differentially
ffecting GR conformation and transcriptional regulation (Meijsing
t al., 2009). Further complexity is revealed at the level of chro-
atin,whereGRbinding is highly dynamic and invariably occurs at
ither consititutive or hormone inducible nuclease accessible sites
regions of “open” chromatin) at which the requirement for chro-
atin remodelling complexes differs (John et al., 2008; Biddie and
ager, 2009). These dynamic and gene-speciﬁc differences in chro-
atin remodelling by GR are likely to be highly cell-speciﬁc andould underlie the complex kinetics of glucocorticoid responses,
here glucocorticoid responsive genes may exhibit alternate acti-
ation and repression,with poor correlation in some cases between
R binding to response elements and target gene response (John
t al., 2009). Elucidating the nature of GR interactions with targetellular Endocrinology 335 (2011) 2–13 5
genes, especially in the immune system, will be crucial to under-
standing their anti-inﬂammatory effects, but the challenge will be
to establish these actions in physiologically relevant settings.
6. Glucocorticoid effects on immune cell function
GR is widely, almost ubiquitously, expressed. Thus, glucocor-
ticoids affect virtually all immune cells and, moreover, precise
effects depend upon differentiation and activation state of the cell
(McEwen et al., 1997), making interpretation of in vivo effects
in speciﬁc cell populations difﬁcult. Nevertheless, several lines of
mice with global alteration of GR have provided vital new infor-
mation about the functions of GR both in regulating the HPA axis
and immunity and inﬂammation. Mice with hypomorphic (GRhypo)
or null alleles of GR die neonatally (Cole et al., 1995; Finotto et
al., 1999), but haematopoietic progenitors from these mice have
been used to reconstitute the immune system in lethally irradi-
ated wild-type mice (Wust et al., 2008). Other models survive and
include mice with increased GR density (yGR mice with 2 extra GR
alleles) (Reichardt et al., 2000), with decreased GR density (GR+/−
mice and anti-sense rat GR transgenic mice, Pepin et al. (1992))
and mice with altered GR function; GRdim (Reichardt et al., 1998)
and GRM601L mice (Zhang et al., 2009) (a knock-in of a human GR
mutantwith increased glucocorticoid sensitivity). In all thesemod-
els the HPA axis is affected because of the central feedback actions
of glucocorticoids, compensating for altered GR function in all but
the hypomorphic and null mice. All show inﬂammatory/immune
phenotypes (see below). Recent experiments using conditional GR
knockout mice as well as transgenic mice have also shed light on
the cell-speciﬁc functions of GR during immune and inﬂammatory
responses. Tissue-speciﬁcmodels reported includeTcell-speciﬁcor
myeloid cell knockout of GR aswell as transgenicmicewith thymus
over- andunder-expressionofGR. Someof the immuneand inﬂam-
matory phenotypes of these various mice have been reviewed in
detail elsewhere (Herold et al., 2006; Kleiman and Tuckermann,
2007) and are discussed below.
6.1. GR functions in T cells
Glucocorticoid action in T cells and, in particular, in thymus,
where naive T cells (that have yet to encounter antigen) develop,
has been the subject of intensive research yet remains highly
controversial. During T cell development, immature thymocytes
progress from double negative (for the CD4 and CD8 T cell mark-
ers) to double positive cells (CD4+CD8+) which undergo positive
selection (only thymocytes that bind MHC complexed with self-
antigen survive) and negative selection (against cells that interact
too strongly with self-antigen) to mature into either CD4+ or CD8+
single positive cells; the T cell repertoire. Double positive cells,
the majority of the thymocyte population, are highly sensitive to
glucocorticoid-induced apoptosis (Purton et al., 2004), effective at
physiological levels of glucocorticoids (Jaffe, 1924). Much in vitro
evidence points to a crucial role for glucocorticoids in regulating
T cell number, repertoire and function, yet the in vivo evidence is
discordant. This topic has been extensively reviewed (Ashwell et
al., 2000; Godfrey et al., 2001; Jondal et al., 2004; Bommhardt et
al., 2004; Herold et al., 2006) and will only be brieﬂy discussed
here. Sufﬁce it to say, complete lack of GR globally, in T cells alone
or inability to dimerise (GRdim mice) does not appear to affect
thymocytenumber or subsets, although these thymocytes are com-
pletely glucocorticoid resistant (Reichardt et al., 1998; Purton et
al., 2000; Cole et al., 2001; Purton et al., 2002; Brewer et al., 2002)
(reviewed in Herold et al. (2006)). Conversely, mice with a global
increase in GR levels (yGR mice) or function (GRM604L mice) have
normal thymocyte numbers and subsets, yet both lines of mice
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how increased glucocorticoid sensitivity of thymocytes in vitro
Reichardt et al., 2000; Zhang et al., 2009). However, transgenic
ice with increased GR in T cells (directed by the proximal Lck
romoter or a doxycycline-inducible CD2 promoter) show reduced
hymic cellularity with increased thymocyte sensitivity to gluco-
orticoids in vitro (Pazirandeh et al., 2002, 2005). Finally, in 2 of 3
odels in which GR density is reduced by expression of antisense
R either globally (neuroﬁlament promoter) or in T cells (Lck pro-
oter), thymic cellularity is increased, albeitmodestly (Pepin et al.,
992; Pazirandeh et al., 2002). However, the 3rd antisense model
also using the proximal Lck promoter) showed the opposite effect,
ith reduced cellularity (King et al., 1995) and altered T cell reper-
oire (Lu et al., 2000). Reconciling these discrepant results will no
oubt inform on the cell-speciﬁc roles of GR in thymus and T cell
election.
T cell GR is required to survive lethal activation of T cells. Mice
ith conditional deletion of GR in T cells (in which the Lck pro-
oter was used to drive Cre recombinase-mediated excision of a
ﬂoxed” GR gene) showed increased mortality following activation
f T cells either by antibody to CD3 or following injection of bacte-
ial superantigen (staphylococcal enterotoxin A), due to failure to
epress cyclooxygenase (COX)-2 expression (Brewer et al., 2003).
nterestingly, these mice showed much worse tissue damage in
he gastrointestinal tract than control mice following T cell acti-
ation, although damage in other tissues was similar (Brewer et
l., 2003), suggesting a particular role for GR in T cells within the
astrointestinal mucosa in controlling immune activation.
GR is also required in peripheral T cells for the immunosuppres-
ive effects of glucocorticoid therapy in experimental autoimmune
ncephalomyelitis (EAE; a mouse model of multiple sclerosis)
Wust et al., 2008). Like chimeric mice with GR−/− haemotopoietic
ells (following lethal irradiation of wild-type mice and reconsti-
ution with GR−/− haemotopoietic cell progenitors), GRLckCre mice
a second line, distinct from the mice mentioned above) showed
n earlier onset of disease than controls (indicating a critical role
or endogenous glucocorticoid) which was refractory to dexam-
thasone treatment (Wust et al., 2008). In control mice, but not
n GRLckCre mice, glucocorticoid therapy induced apoptosis of T
ells in peripheral lymphoid organs and down-regulated adhesion
olecules, thus reducing migration of T cells to the site of inﬂam-
ation (Wust et al., 2008). Importantly, mice heterozygous for a
ull mutation of GR (GR+/− mice), with half the normal level of GR
Wang et al., 2006), showed a more severe EAE disease course with
reater inﬂammation in the spinal cord than controlmice andwere
esistant to the suppressive effects of a sub-maximal dose of dex-
methasone (4mg/kg) that was effective in normal mice (Wust et
l., 2008). This suggests that GR density in peripheral T cells is a
ritical determinant of sensitivity and that despite the presence
f functional GR, clinical glucocorticoid resistance can arise. How-
ver, in sepsis, another model of inﬂammation, GR in T cells is not
equired for glucocorticoid suppression (cited as unpublished data
n Kleiman and Tuckermann (2007)).
.2. GR functions in myeloid cells
The phenotype of mice with a conditional deletion of GR in
yeloid cells has been reported by 2 groups (Bhattacharyya et
l., 2007; Tuckermann et al., 2007; Wust et al., 2008). In both
ases, the LysM promoter was used to drive Cre recombinase-
ediated excision of a ﬂoxed GR gene. This results in efﬁcient
xcision in macrophages and granulocytes in GRLsyMCre mice, with
ariable excision in other myeloid cell types including dendritic
ells and mast cells (Clausen et al., 1999; Lacy-Hulbert et al., 2007;
uckermannet al., 2007). Similar to adrenalectomisedmice (Bertini
t al., 1988),GRLsyMCre mice showed greatermortality following LPS
hallenge than control mice (Bhattacharyya et al., 2007). This wasellular Endocrinology 335 (2011) 2–13
attributed to failure to induce DUSP1, required to inhibit p38MAPK
activated by engagement of toll-like receptor (TLR) 4 by LPS (Zhao
et al., 2006). However, given that GRdim mice show normal glu-
cocorticoid induction of DUSP1 in macrophages (Abraham et al.,
2006), yet are susceptible to lethal sepsis (cited in Kleiman and
Tuckermann (2007)) as unpublished data), it is likely that other
important myeloid cell anti-inﬂammatory actions of glucocorti-
coids are also required in this model of inﬂammation. In contrast to
endotoxaemia, mice with deletion of GR in myeloid cells remained
fully sensitive to therapeutic suppression of EAE by glucocorticoid,
although they did show exacerbated disease (Wust et al., 2008).
GR in myeloid cells, but not T cells, are required for glu-
cocorticoid suppression of contact allergy (a T cell-dependent
delayed-type hypersensitivity response, such as occurs in response
to metals or poison ivy) (Tuckermann et al., 2007). Whereas T cell
deletion of GR (GRLckCre) had no effect, deletion of GR in myeloid
cells (GRLysMCre) abolished glucocorticoid suppression of inﬂam-
mation, allowed persistent leukocyte inﬁltration into the inﬂamed
areaand impairedglucocorticoid suppressionofmacrophage IL-1,
MCP-1andMIP-2secretion (Tuckermannetal., 2007). Interestingly,
in contrast to irritant-induced skin inﬂammation (Reichardt et al.,
2001), glucocorticoid repressionof T cell-dependent contact allergy
did not occur inGRdim mice (Tuckermann et al., 2007), and although
TNF remainedglucocorticoid-suppressible inGRdim macrophages,
MCP-1 and MIP-2 were not repressed (Tuckermann et al., 2007).
Thus, the immunosuppressive effects of GR are likely to result
from multiple mechanisms, which are cell-type and stimulus-type
dependent.
The elucidation of the cell-speciﬁc roles of GR within other
leukocyte populations and also within T cell subsets will be
informed by future conditional knockouts. Knockout of GR in
mast cells, a major target in glucocorticoid suppression of aller-
gic responses (Kassel and Cato, 2002), will be revealing, as will GR
disruption in B cells. Like T cells, glucocorticoids also reduce circu-
lating B cell numbers. Consistentwith this, blood lymphocyte levels
(T and B cells) aswell asmonocyte/neutrophils (CD11b+ cells)were
markedly reduced following reconstitution of irradiated wild-type
mice with GRM604L glucocorticoid-hypersensitive haematopoietic
progenitor cells (Zhang et al., 2009). Elucidation of the underlying
mechanisms may be helpful in the treatment of some early T and
B cell leukaemias that respond to glucocorticoids.
7. Glucocorticoids alter leukocyte differentiation
programmes
As well as profoundly affecting the function of immune cells,
glucocorticoids also alter differentiation programmes of progenitor
cells (McEwen et al., 1997). Thus, chronically stressful conditions
(when endogenous glucocorticoid production is high) or glucocor-
ticoid pharmacotherapy may alter immune cell differentiation and
indeed, probably shape the immune responseas it develops (Munck
et al., 1984; Rook et al., 1994). Thismaybeof relevance in the induc-
tion of peripheral tolerance to allergenic stimuli, a major clinical
application of glucocorticoids.
Dendritic cells are key antigen presenting cells that bridge the
innate and adaptive immune systems. Immature dendritic cells
are activated when they capture, process, then present antigens,
maturing into immunostimulatory cells in the process. Activated
dendritic cells migrate to draining lymph nodes where they inter-
act with naive T cells to instruct the adaptive immune response.
Suppression of dendritic cells maturation and function has been
implicated in the immunosuppressive effects of glucocorticoids.
However, glucocorticoids do not merely suppress dendritic cell
activity, but reprogramme them to so-called “tolerogenic den-
dritic cells” which can elicit a state of hypo-responsiveness in T
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ells and induce formation of regulatory T (Treg) cells (Rea et al.,
000; Rutella and Lemoli, 2004; Chamorro et al., 2009; Luther et
l., 2009). Differentiation of tolerogenic dendritic cells is depen-
ent, at least in part, on GILZ (Cohen et al., 2006; Hamdi et
l., 2007). Exactly how GILZ mediates anti-inﬂammatory effects
urrently remains unclear, although it is likely to depend on
rotein-protein interactions between GILZ and a variety of intra-
ellular signalling proteins, including the inﬂammatory regulators
F-B and activated Ras, the latter being a key protein in sig-
alling to MAP kinases (Ayroldi and Riccardi, 2009). Nevertheless,
he active suppression of antigen-speciﬁc immunity through Treg
nduction by glucocorticoid-programmed dendritic cells undoubt-
dly contributes to their efﬁcacy in allergic disease and probably
ther chronic inﬂammatory diseases. Interestingly, as well as
romoting a tolerogenic phenotype in dendritic cells, glucocor-
icoids may also contribute to tolerance through direct effects
n T cells. Stimulation of CD4+ cells in the presence of gluco-
orticoid (or even more effectively, together with vitamin D3)
nduced IL-10-secreting Treg cells, able to regulate Th1 responses
nd autoimmunity (Richards et al., 2000; Hawrylowicz, 2005). A
ore complete understanding of these effects will improve clinical
se of glucocorticoids.
These dramatic effects of glucocorticoids on haematopoietic cell
ifferentiation are not restricted to dendritic cells. Glucocorticoids
nduce a similar anti-inﬂammatory phenotype in macrophage dif-
erentiation. Work over the past decade has shown that a key
echanism to resolve inﬂammation is the recognition and phago-
ytosis of dying cells by monocytes/macrophages (Savill et al.,
002). Glucocorticoids increase macrophage phagocytosis of apop-
otic cells, a strongly anti-inﬂammatory process (Fadok et al.,
998), by at least 2 mechanisms. In already differentiated human
onocyte-derived macrophages, they induce a protein S/Mer tyro-
ine kinase-dependent apoptotic cell clearance pathway (McColl
t al., 2009). However, when included during the differentiation
rocess, glucocorticoids also programme bloodmonocyte differen-
iation into a highly phagocytic “anti-inﬂammatory” macrophage
henotype (Giles et al., 2001; Heasman et al., 2003; Ehrchen et al.,
007), a phenomenon that canbemodulatedby local cytokine envi-
onment (Heasman et al., 2003), may be mediated in part by Anxa1
Maderna et al., 2005) and which also includes induction of Mer
yrosine kinase as well as other anti-inﬂammatory genes impor-
ant in phagocytosis, chemotaxis and protection against oxidative
tress (Ehrchenet al., 2007).WhetherGILZplaysa similar important
ole in the glucocorticoid-directedmacrophage differentiation pro-
ramme to that it plays in re-programming dendritic cells has not
een addressed. Interestingly, these glucocorticoid-programmed
acrophages show down-regulation of adhesion-related proteins
Giles et al., 2001; Ehrchen et al., 2007) suggesting they have
ncreased migratory properties. Importantly, in mouse monocytes,
lucocorticoids induced a phenotype with low adhesiveness, high
igratory capacity and markers suggestive of a tumour-associated
acrophage phenotype (Varga et al., 2008), believed to be impor-
ant for tumour-associated immunosuppression (Sica and Bronte,
007). The authors further speculate that this may be a mechanism
nderlying the higher incidence and faster progression of tumours
n patients on long-termglucocorticoid therapy (Varga et al., 2008).
ntriguingly, in aged mice, elevated plasma glucocorticoid levels
ere associated with an increase in the proportion of suppressor
acrophages in spleen (Kizaki et al., 1998), suggesting that endoge-
ous glucocorticoids may regulate macrophage phenotype in vivo,
imilar to the potent synthetic glucocorticoids used in the in vitro
tudies. However, further clariﬁcation of the macrophage pheno-
ypes involved in both the in vivo and in vitro studies is required
efore conclusions can be drawn concerning the involvement
f glucocorticoids in suppressor macrophage differentiation and
unction.ellular Endocrinology 335 (2011) 2–13 7
8. GR agonists; pharmacological and physiological GR
activation
A variety of GR ligands are in use clinically which have dif-
ferent potency and differ in their biological efﬁcacy. Different
ligands clearly induce different conformations of GR that have dif-
ferent gene regulatory properties (Croxtall et al., 2002; Elmore
et al., 2004) - indeed this has recently been exploited in the
search for “dissociated” ligands which dissociate the beneﬁcial
anti-inﬂammatory (repressive) effects of GR agonism from the
unwanted metabolic (activation) effects (Schacke et al., 2007;
De Bosscher and Haegeman, 2009). Structural studies, including
of dexamethasone, ﬂuticasone fuorate and, more recently non-
steroidal agonists bound in the GR ligand binding domain have
shownthatGRreadily changes conformation toaccommodate large
moieties on the ligand and have illustrated new possibilities for
mode of ligand binding to GR (Madauss et al., 2008; Biggadike et al.,
2009). Thus, different conformations of GR resulting from different
ligand associations may have cell-speciﬁc and target gene-speciﬁc
properties that offer potential for future pharmacological exploita-
tion.
8.1. Endogenous glucocorticoid action
Much of the research on the anti-inﬂammatory and immuno-
suppressive actions of glucocorticoids has been carried out with
saturating levels of synthetic hormones. In humans, these include
prednisolone and methylprednisolone, but in animal models and
in vitro, dexamethasone is most commonly used. This has pro-
vided an over-simpliﬁed view of the immunomodulatory actions
of glucocorticoids and may have overlooked important opportu-
nities for therapeutic manipulation of endogenous glucocorticoid
action. This subject has been previously reviewed (Munck et al.,
1984; Wilckens, 1995; Wilckens and De Rijk, 1997; Yeager et al.,
2004; Simons, 2008), and the discussion here is restricted to more
recent insights.
Synthetic glucocorticoids, especially dexamethasone, have
higher afﬁnity, greater bioavailability (unlike the natural hor-
mones, most bind poorly or not at all to corticosteroid binding
globulin) and are poorly metabolised, thus they persist in plasma
much longer than endogenous glucocorticoids (cortisol, corticos-
terone).Moreover, the endogenoushormones are released fromthe
adrenal gland in both a circadian and a highly pulsatile (ultradian)
manner (reviewed in (Lightman,2008)). Recentwork fromthe labo-
ratories of GordonHager and Stafford Lightmanhas shown that this
pulsatile release of glucocorticoids is coupled to a highly dynamic
patternofGR-mediated transcriptionalbursts, drivenby rapid recy-
cling of GR occupancy of chromatin binding sites in response to the
hormonal pulses in vivoaswell as in vitro (Stavrevaet al., 2009). This
pulsatility did not occur with constant administration of hormone,
nor did it happen with synthetic ligands, including dexametha-
sone, which failed to cause signiﬁcant ultradian cycling of GR on
chromatin and consequently failed to couple ﬂuctuations in hor-
mone levels with transcriptional response (Stavreva et al., 2009).
Thus, transcriptional output can be profoundly altered by synthetic
GR ligands or even with natural hormones if not administered in
the natural pattern (Stavreva et al., 2009). Moreover, basal levels
of glucocorticoids in vivo exert tonic effects. Thus, macrophages
elicited by thioglycollate in the peritoneum of adrenalectomised
rats behaved very differently to macrophages from sham operated
rats, with much greater TNF secretion and NO production in the
unstimulated state, which could only be marginally increased by
LPS/IFN stimulation (Lim et al., 2007). Cytokines themselves are
potent activators of the HPA axis (Besedovsky and del Rey, 1996;
Webster et al., 2002; Sternberg, 2006), and may permanently pro-
gramme endogenous glucocorticoid secretion when elevated in
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arly life (Shanks et al., 2000). Importantly, when the HPA axis is
ctivated, not only is plasma cortisol elevated (corticosterone in
odents), but so is plasma cortisone (11-dehydrocorticosterone in
odents), itself intrinsically inert due to poor binding to GR, but
hich is available in plasma (it shows negligible binding to corti-
osteroid binding globulin) andwhich can be readily enzymatically
onverted inside cells to the active steroid by 11-hydroxysteroid
ehydrogenase type 1 (11-HSD1).
. 11-HSD1 ampliﬁes glucocorticoid action within cells
The last 2 decades have produced a wealth of information
n the importance of pre-receptor steroid metabolism. By inter-
onverting active glucocorticoids and inert 11-keto metabolites
cortisone, 11-dehydrocorticosterone), 11-HSD modulates intra-
ellular access of glucocorticoid to receptors. Type 2 11-HSD
11-HSD2) inactivates glucocorticoids in vivo, thus protecting
he otherwise non-selective MR from occupation by glucocorti-
oids (Funder, 1997; Seckl, 2000). In contrast, because 11-HSD1
eactivates glucocorticoids, it increases intracellular glucocorticoid
oncentration. In addition to cortisone (the natural metabolite),
ertain synthetic steroids (notably prednisone/prednisolone) are
lso substrates for the 11-HSD enzymes. The reaction direction of
1-HSD1 is dictated by its association with hexose-6-phosphate
ehydrogenase (H6PD), which couples glucose-6-phosphate oxi-
ation to NADP reduction, generating NADPH co-factor to drive
1-HSD1 reductase activity (White et al., 2007; Atanasov et
l., 2008). 11-HSD1 has attracted a lot of recent attention as a
otential therapeutic target for metabolic disease, with inhibitors
urrently under clinical development (Boyle and Kowalski, 2009;
osenstock et al., 2009). Overexpression of 11-HSD1 in adipose
issue is associated with obesity in both humans and rodents and
n transgenic mice, additionally causes hypertension and insulin
esistance (reviewed in Seckl et al. (2004)). Conversely, inhibi-
ion of, or deﬁciency in 11-HSD1 reduces hyperglycemia and
mproves insulin sensitivity in non-insulin dependent diabetes in
umans and rodents (Seckl et al., 2004). Selective inhibition of 11-
SD1alsopreventedprogressionof atherosclerosis inApoe−/− mice
nd lowered levels of circulating MCP-1, a cytokine that recruits
onocytes to sites of injury (Hermanowski-Vosatka et al., 2005).
t will be important to determine the extent to which these pro-
nﬂammatory effects of 11-HSD1 are due to its dysregulation in
dipose tissue and possibly other tissues in metabolic disease.
11-HSD1 is widely expressed, with highest expression in
lassical glucocorticoid target tissues (Whorwood et al., 1992).
iven the crucial immunomodulatory actions of glucocorticoids
nd the strong association between inﬂammation and insulin resis-
ance/metabolic disease, the role of 11-HSD1 in the inﬂammatory
esponse is of great interest. This area has been recently reviewed
Chapman et al., 2006a,b, 2009; Cooper and Stewart, 2009) and the
iscussion here is restricted to recent developments and questions.
Like GR, 11-HSD1 is widely expressed in immune cells, but
ts expression is highly dependent on the differentiation and
ctivation state of the cell. Circulating leukocytes show little
r no 11-HSD1 expression (Thieringer et al., 2001; Gilmour
t al., 2006; Fiore et al., 2009), consistent with negligible 11-
SD1 activity in monocytes (Thieringer et al., 2001) and low
evels in lymphocytes (Hennebold et al., 1996) and neutrophils
Kardon et al., 2008). However, following differentiation of mono-
ytes to macrophages (Thieringer et al., 2001) or dendritic
ells (Freeman et al., 2005), 11-HSD1 activity is dramatically
ncreased and is further increased with polarisation to “M1” pro-
nﬂammatory macrophages compared to “M2” anti-inﬂammatory
acrophages (Martinez et al., 2006). Ampliﬁcation of endoge-
ous glucocorticoids by 11-HSD1 may inﬂuence macrophageellular Endocrinology 335 (2011) 2–13
state as thioglycollate-elicited peritoneal macrophages from 11-
HSD1-deﬁcientmice showed increasedpro-inﬂammatory cytokine
production following LPS stimulation in vitro, in the absence
of added 11-HSD1 substrate (Gilmour et al., 2006; Zhang and
Daynes, 2007) as well as in vivo (Zhang and Daynes, 2007).
Interestingly, macrophage 11-HSD1 is down-regulated follow-
ing phagocytosis of apoptotic neutrophils; a pro-resolution process
(Chapman et al., 2009). The down-regulation of 11-HSD1 may be
part of this mechanism to terminate inﬂammation. In the absence
of 11-HSD1, mice are more sensitive to endotoxaemia (Zhang and
Daynes, 2007), acute inﬂammation is more severe (Coutinho et al.,
2006), and pro-resolution mechanisms may be delayed (Gilmour
et al., 2006). We have recently found 11-HSD1 expression and
activity in mast cells, key initiators of acute inﬂammation and crit-
ical targets of the anti-inﬂammatory actions of glucocorticoids in
allergy (Coutinho et al., 2006). Mast cells from 11-HSD1-deﬁcient
mice are hypersensitive to degranulating stimuli (Coutinho et al.,
2006), suggesting that endogenous glucocorticoid ampliﬁcation
via 11-HSD1 restrains their activity. This may be analagous to
dendritic cells where it has also been suggested that 11-HSD1
activity, which is set at high levels in immature dendritic cells
and decreases following CD40 activation (a signal that supports
cytotoxic T cell differentiation O’Sullivan and Thomas (2002)), may
raise the threshold for dendritic cell-induced immune activation,
by increasing glucocorticoid actionwithin immature dendritic cells
(Freeman et al., 2005).
Within lymphoid cells, 11-HSD1 activity is present at low lev-
els (Zhang et al., 2005) but is increased following activation of CD4+
T cells through the T cell receptor or following polarisation into
Th1 or Th2 cells (Zhang et al., 2005), possibly enhancing the ability
of endogenous glucocorticoids to suppress Th1 cytokines (in Th1
cells) as well as sparing or promoting Th2 cytokine production by
Th2 cells. Thymocytes also express low levels of 11-HSD1, which
is markedly increased, in parallel with GR levels, by burn injury in
mice (D’Elia et al., 2009), a strong stimulus to the HPA axis (Hawes
et al., 1995). The increase in 11-HSD1 activitywas associatedwith
an increased rate of thymocyte apoptosis (D’Elia et al., 2009). The
same may be true in human lymphocyte precursors. In a recent
study in acute lymphoblastic leukaemia (ALL) patients, glucocor-
ticoid treatment increased both 11-HSD1 and GR mRNA levels
in glucocorticoid-sensitive leukaemic cells, but decreased 11-
HSD1 mRNA levels in cells resistant to the pro-apoptotic effects
of glucocorticoids (Sai et al., 2009). This combination of increased
11-HSD1 and GR expression is likely to contribute very signiﬁ-
cantly to the increased glucocorticoid sensitivity of the leukaemic
cells, though whether low 11-HSD1 and GR expression is a cause
or an effect of the glucocorticoid resistance in glucocorticoid-
resistant leukaemia remains to be determined.
Of great interest is the relevance of 11-HSD1 to human inﬂam-
matory disease. 11-HSD1 expression is increased in a cell-speciﬁc
manner by pro-inﬂammatory cytokines, particularly IL-1 and TNF
(reviewed Chapman et al. (2006a,b, 2009), Cooper and Stewart
(2009)) and at sites of inﬂammation (Ergang et al., 2007; Zbankova
et al., 2007; Ahmed et al., 2008; Hardy et al., 2008; Jang et al., 2009).
However, it may be decreased in others. Recent data have shown
decreased 11-HSD1 mRNA levels in lung in a mouse model of
tuberculosis (Abbott et al., 2009), where, similar to other inﬂam-
matory conditions, 11-HSD1 shows a reciprocal regulation to
11-HSD2 (Ergang et al., 2007; Abbott et al., 2009). An even fur-
ther level of complexity is revealed by the ﬁndings that in human
rheumatoid arthritis, 11-HSD1 is increased in synovial ﬁbrob-
lasts, whereas synovial macrophages express 11-HSD2 (Hardy
et al., 2008); suggesting a complex control over glucocorticoid
availability within the rheumatic joint. 11-HSD2 is not normally
expressed in macrophages (Thieringer et al., 2001; Gilmour et al.,
2006), nor is it expressed here during acute inﬂammation, at least
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n mice (Thieringer et al., 2001; Gilmour et al., 2006). However,
ther groups have also reported 11-HSD2 expression in rheuma-
oid arthritis patients in synovial macrophages (Schmidt et al.,
005), immortalised B cells (Haas et al., 2006) and peripheral blood
ononuclear cells (Olsen et al., 2004). Whether this is part of an
daptive response to inﬂammation or contributes to glucocorticoid
esistance will be important to establish.
Finally, recentwork is starting to elucidate themechanisms that
egulate 11-HSD1 expression. Whilst the C/EBP family of tran-
cription factors (McKnight, 2001; Nerlov, 2007) was implicated
ome years ago (Williams et al., 2000), recent data have shown
he pivotal role of C/EBP in the adipocyte expression and tissue-
peciﬁc regulation of 11-HSD1 (Gout et al., 2006; Arai et al., 2007;
ayne et al., 2007), and importantly, inmediating the effects of pro-
nﬂammatory mediators on transcription of the gene (Ignatova et
l., 2009; Yang et al., 2009b). C/EBP has also been implicated in
he glucocorticoid-induction of 11-HSD1 in adipose tissue (Sai et
l., 2008), although this may be a tissue-speciﬁc mechanism (Sai et
l., 2008; Yang et al., 2007). Given that C/EBP occupies a pivotal
osition in the integration of metabolic and inﬂammatory signals
Hu et al., 2007; Millward et al., 2007; Schroeder-Gloeckler et al.,
007; Cho et al., 2008; Staiger et al., 2008; Du and Ding, 2009; Ito et
l., 2009; Ruffell et al., 2009), is a critical component of some gluco-
orticoid responsive units (e.g. Croniger et al. (1997), Savoldi et al.
1997) and Yamada et al. (1999)) and is also a glucocorticoid target
ene itself, being regulated at both mRNA and post-translational
evels by glucocorticoids in a tissue-speciﬁc manner (Gotoh et al.,
997; Kimura et al., 2001; Penner et al., 2002; Berg et al., 2005;
ang et al., 2005a,b), it will be extremely informative to unravel
he associations between C/EBP, 11-HSD1 and glucocorticoids
n determination of immune cell differentiation and function.
0. Summary and conclusions
Many aspects of the anti-inﬂammatory actions of glucocorti-
oids have not been covered here. However, it is clear that the
eld is at an exciting stage. The next few years should provide a
ig step forward in our understanding of how these important hor-
ones exert their effects,with concomitant advances in the clinical
reatment of inﬂammatory disease.
cknowledgements
Work in the authors’ laboratory is funded by grants from The
edical Research Council and The Wellcome Trust. We thank our
olleagues in the Endocrinology Unit and the Centre for Inﬂamma-
ion Research for many stimulating discussions. We apologise to
hose whose work we have been unable to include or which may
nadvertently have escaped our attention.
eferences
bbott, A.N., Guidry, T.V., Welsh, K.J., Thomas, A.M., Kling, M.A., Hunter, R.L.,
Actor, J.K., 2009. 11-HydroxysteroidDehydrogenases Are Regulated during the
PulmonaryGranulomatousResponse to theMycobacterialGlycolipidTrehalose-
6,6’-Dimycolate. Neuroimmunomodulation 16, 147–154.
braham, S.M., Lawrence, T., Kleiman, A., Warden, P., Medghalchi, M., Tuckermann,
J., Saklatvala, J., Clark, A.R., 2006. Antiinﬂammatory effects of dexamethasone
are partly dependent on induction of dual speciﬁcity phosphatase 1. J. Exp. Med.
203, 1883–1889.
dams, M., Meijer, O.C., Wang, J., Bhargava, A., Pearce, D., 2003. Homodimer-
ization of the glucocorticoid receptor is not essential for response element
binding: activation of the phenylethanolamine N-methyltransferase gene by
dimerization-defective mutants. Mol. Endocrinol. 17, 2583–2592.
hmed,A., Saksena, S., Sherlock,M.,Olliff, S.P., Elias, E., Stewart, P.M., 2008. Induction
of hepatic 11-hydroxysteroid dehydrogenase type 1 in patients with alcoholic
liver disease. Clin. Endocrinol. (Oxf) 68, 898–903.
lam, T., An, M.R., Mifﬂin, R.C., Hsieh, C.-C., Ge, X., Papaconstantinou, J., 1993. Trans-
activation of the 1-acid glycoprotein gene acute phase responsive elementellular Endocrinology 335 (2011) 2–13 9
by multiple isoforms of C/EBP and glucocorticoid receptor. J. Biol. Chem. 268,
15681–15688.
Arai, N., Masuzaki, H., Tanaka, T., Ishii, T., Yasue, S., Kobayashi, N., Tomita, T.,
Noguchi, M., Kusakabe, T., Fujikura, J., Ebihara, K., Hirata, M., Hosoda, K.,
Hayashi, T., Sawai, H., Minokoshi, Y., Nakao, K., 2007. Ceramide and adeno-
sine 5’-monophosphate-activated protein kinase are two novel regulators of
11-hydroxysteroid dehydrogenase type 1 expression and activity in cultured
preadipocytes. Endocrinology 148, 5268–5277.
Ashwell, J.D., Lu, F.W., Vacchio, M.S., 2000. Glucocorticoids in T cell development
and function. Ann. Rev. Immunol. 18, 309–345.
Atanasov, A.G., Nashev, L.G., Gelman, L., Legeza, B., Sack, R., Portmann, R., Odermatt,
A., 2008. Direct protein-protein interaction of 11-hydroxysteroid dehydro-
genase type 1 and hexose-6-phosphate dehydrogenase in the endoplasmic
reticulum lumen. Biochim. Biophys. Acta 1783, 1536–1543.
Auphan, N., DiDonato, J.A., Rosette, C., Helmberg, A., Karin, M., 1995. Immunosu-
pression by glucocorticoids: inhibition of NF-B activity through induction of
IB synthesis. Science 270, 286–290.
Ayroldi, E., Riccardi, C., 2009. Glucocorticoid-induced leucine zipper (GILZ): a new
important mediator of glucocorticoid action. FASEB J. 23, 3649–3658.
Barish, G.D., Downes, M., Alaynick, W.A., Yu, R.T., Ocampo, C.B., Bookout, A.L.,
Mangelsdorf, D.J., Evans, R.M., 2005. A Nuclear Receptor Atlas: macrophage
activation. Mol. Endocrinol. 19, 2466–2477.
Barnes, P.J., 1998. Anti-inﬂammatory actions of glucocorticoids: molecular mecha-
nisms. Clin. Sci. (Lond) 94, 557–572.
Beato, M., Chalepakis, G., Schauer, M., Slater, E.P., 1989. DNA regulatory elements
for steroid hormones. J. Steroid Biochem. 32, 737–748.
Beato, M., Chavez, S., Truss, M., 1996. Transcriptional regulation by steroid hor-
mones. Steroids 61, 240–251.
Berg, T., Didon, L., Barton, J., Andersson, O., Nord, M., 2005. Glucocorticoids increase
C/EBP activity in the lung epithelium via phosphorylation. Biochem. Biophys.
Res. Commun. 334, 638–645.
Bertini, R., Bianchi, M., Ghezzi, P., 1988. Adrenalectomy sensitizes mice to the lethal
effects of Interleukin-1 and Tumor Necrosis Factor. J. Exp. Med. 167, 1708–1712.
Besedovsky,H.O., del Rey,A., 1996. Immune-neuro-endocrine interactions: facts and
hypotheses. Endocr. Rev. 17, 64–102.
Bhattacharyya, S., Brown, D.E., Brewer, J.A., Vogt, S.K., Muglia, L.J., 2007. Macrophage
glucocorticoid receptors regulate Toll-like receptor-4-mediated inﬂammatory
responses by selective inhibition of p38 MAP kinase. Blood 109, 4313–4319.
Biddie, S.C., Hager, G.L., 2009.Glucocorticoid receptor dynamics andgene regulation.
Stress 12, 193–205.
Biggadike, K., Bledsoe, R.K., Coe, D.M., Cooper, T.W., House, D., Iannone, M.A., Mac-
donald, S.J., Madauss, K.P., McLay, I.M., Shipley, T.J., Taylor, S.J., Tran, T.B., Uings,
I.J., Weller, V., Williams, S.P., 2009. Design and X-ray crystal structures of high-
potency nonsteroidal glucocorticoid agonists exploiting a novel binding site on
the receptor. Proc. Natl. Acad. Sci. U.S.A. 106, 18114–18119.
Blind, R.D., Garabedian, M.J., 2008. Differential recruitment of glucocorticoid recep-
tor phospho-isoforms to glucocorticoid-induced genes. J. Steroid Biochem. Mol.
Biol. 109, 150–157.
Bommhardt, U., Beyer, M., Hunig, T., Reichardt, H.M., 2004. Molecular and cellular
mechanisms of T cell development. Cell. Mol. Life Sci. 61, 263–280.
Boyle, C.D., Kowalski, T.J., 2009. 11-hydroxysteroid dehydrogenase type 1
inhibitors: a review of recent patents. Expert Opin. Ther. Pat. 19, 801–825.
Brewer, J.A., Kanagawa, O., Sleckman, B.P., Muglia, L.J., 2002. Thymocyte apoptosis
induced by T cell activation is mediated by glucocorticoids in vivo. J. Immunol.
169, 1837–1843.
Brewer, J.A., Khor, B., Vogt, S.K., Muglia, L.M., Fujiwara, H., Haegele, K.E., Sleckman,
B.P.,Muglia, L.J., 2003. T-cell glucocorticoid receptor is required to suppressCOX-
2-mediated lethal immune activation. Nat. Med. 9, 1318–1322.
Cannarile, L., Cuzzocrea, S., Santucci, L., Agostini,M.,Mazzon, E., Esposito, E.,Muia, C.,
Coppo, M., Di Paola, R., Riccardi, C., 2009. Glucocorticoid-induced leucine zipper
is protective in Th1-mediated models of colitis. Gastroenterology 136, 530–541.
Cannarile, L., Fallarino, F., Agostini, M., Cuzzocrea, S., Mazzon, E., Vacca, C., Gen-
ovese, T., Migliorati, G., Ayroldi, E., Riccardi, C., 2006. Increased GILZ expression
in transgenic mice up-regulates Th-2 lymphokines. Blood 107, 1039–1047.
Chamorro, S., Garcia-Vallejo, J.J., Unger, W.W., Fernandes, R.J., Bruijns, S.C., Laban,
S., Roep, B.O., t Hart, B.A., van Kooyk, Y., 2009. TLR triggering on tolerogenic
dendritic cells results in TLR2 up-regulation and a reduced proinﬂammatory
immune program. J. Immunol. 183, 2984–2994.
Chapman, K.E., Coutinho, A., Gray, M., Gilmour, J.S., Savill, J.S., Seckl, J.R., 2006a.
Local ampliﬁcation of glucocorticoids by 11-hydroxysteroid dehydrogenase
type 1 and its role in the inﬂammatory response. Ann. N.Y. Acad. Sci. 1088, 265–
273.
Chapman, K.E., Coutinho, A.E., Gray, M., Gilmour, J.S., Savill, J.S., Seckl, J.R., 2009.
The role and regulation of 11-hydroxysteroid dehydrogenase type 1 in the
inﬂammatory response. Mol. Cell. Endocrinol. 301, 123–131.
Chapman, K.E., Gilmour, J.S., Coutinho, A.E., Savill, J.S., Seckl, J.R., 2006b. 11-
hydroxysteroid dehydrogenase type 1- a role in inﬂammation? Mol. Cell
Endocrinol. 248, 3–8.
Cho, I.J., Woo, N.R., Kim, S.G., 2008. The identiﬁcation of C/EBP as a transcription
factornecessary for the inductionofMAPKphosphatase-1by toll-like receptor-4
ligand. Arch. Biochem. Biophys. 479, 88–96.
Clark, A.R., 2007. Anti-inﬂammatory functions of glucocorticoid-induced genes.Mol.
Cell. Endocrinol. 275, 79–97.
Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R., Forster, I., 1999. Conditional
gene targeting in macrophages and granulocytes using LysMcre mice. Trans-
genic Res. 8, 265–277.
1 and C
C
C
C
C
C
C
C
C
D
D
D
D
D
d
D
D
E
E
E
F
F
F
F
F
F0 A.E. Coutinho, K.E. Chapman / Molecular
ohen,N.,Mouly, E., Hamdi,H.,Maillot,M.-C., Pallardy,M., Godot, V., Capel, F., Balian,
A., Naveau, S., Galanaud, P., Lemoine, F.M., Emilie, D., 2006. GILZ expression in
human dendritic cells redirects their maturation and prevents antigen-speciﬁc
T lymphocyte response. Blood 107, 2037–2044.
ole, T., Blendy, J.A., Monaghan, A.P., Kriegelstein, K., Schmid, W., Fantuzzi, G.,
Hummler, E., Unsicker, K., Schütz, G., 1995. Targeted disruption of the gluco-
corticoid receptor blocks adrenergic chromafﬁn cell development and severely
retards lung maturation. Genes Dev. 9, 1608–1621.
ole, T.J., Myles, K., Purton, J.F., Brereton, P.S., Solomon, N.M., Godfrey, D.I., Funder,
J.W., 2001. GRKO mice express an aberrant dexamethasone-binding glucocorti-
coid receptor, but are profoundly glucocorticoid resistant. Mol. Cell. Endocrinol.
173, 193–202.
ooper, M.S., Stewart, P.M., 2009. 11-Hydroxysteroid dehydrogenase type 1 and
its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and
inﬂammation. J. Clin. Endocrinol. Metab. (October (16)), Epub ahead of print.
ouper, K.N., Blount, D.G., Riley, E.M., 2008. IL-10: the master regulator of immunity
to infection. J. Immunol. 180, 5771–5777.
outinho, A.E., Gray, M., Sawatzky, D.A., Brownstein, D., Gilmour, J.S., Mullins, J.,
Seckl, J.R., Savill, J.S., Chapman, K.E., 2006. Deﬁciency in 11-hydroxysteroid
dehydrogenase type 1 results in a more rapid and severe inﬂammation. In:
Abstracts of the 88th meeting of the American Endocrine Society, pp. 2–108.
roniger, C., Trus, M., Lysek-Stupp, K., Cohen, H., Liu, Y., Darlington, G.J., Poli, V.,
Hanson, R.W., Reshef, L., 1997. Role of the isoforms of CCAAT/enhancer-binding
protein in the initiationof phosphoenolpyruvate carboxykinase (GTP) gene tran-
scription at birth. J. Biol. Chem. 272, 26306–26312.
roxtall, J.D., van Hal, P.T., Choudhury, Q., Gilroy, D.W., Flower, R.J., 2002. Different
glucocorticoids vary in their genomic and non-genomic mechanism of action in
A549 cells. Br. J. Pharmacol. 135, 511–519.
’Acquisto, F., Merghani, A., Lecona, E., Rosignoli, G., Raza, K., Buckley, C.D., Flower,
R.J., Perretti, M., 2007a. Annexin-1 modulates T-cell activation and differentia-
tion. Blood 109, 1095–1102.
’Acquisto, F., Paschalidis, N., Raza, K., Buckley, C.D., Flower, R.J., Perretti, M., 2008.
Glucocorticoid treatment inhibits annexin-1 expression in rheumatoid arthritis
CD4+ T cells. Rheumatology (Oxford) 47, 636–639.
’Acquisto, F., Paschalidis, N., Sampaio, A.L., Merghani, A., Flower, R.J., Perretti, M.,
2007b. Impaired T cell activation and increased Th2 lineage commitment in
Annexin-1-deﬁcient T cells. Eur. J. Immunol. 37, 3131–3142.
’Elia, M., Patenaude, J., Bernier, J., 2009. Regulation of glucocorticoid sensitivity
in thymocytes from burn-injured mice. Am. J. Physiol. Endocrinol. Metab. 296,
E97–E104.
e Bosscher, K., Haegeman, G., 2009. Latest perspectives on anti-inﬂammatory
actions of glucocorticoids. Mol. Endocrinol. 23, 281–291.
e Vries, F., Pouwels, S., Lammers, J.W., Leufkens, H.G., Bracke, M., CooperF C., van
Staa, T.P., 2007. Use of inhaled and oral glucocorticoids, severity of inﬂammatory
disease and risk of hip/femur fracture: a population-based case-control study.
J. Intern. Med. 261, 170–177.
elﬁno, D.V., Agostini, M., Spinicelli, S., Vacca, C., Riccardi, C., 2006. Inhibited
cell death, NF-|B activity and increased IL-10 in TCR-triggered thymocytes of
transgenic mice overexpressing the glucocorticoid-induced protein GILZ. Int.
Immunopharmacol. 6, 1126–1134.
u, K., Ding, J., 2009. Insulin Regulates TRB3 and Other Stress Responsive Gene
Expression through Induction of C/EBP. Mol. Endocrinol. 23, 475–485.
hrchen, J., Steinmuller, L., Barczyk, K., Tenbrock, K., Nacken, W., Eisenacher, M.,
Nordhues, U., Sorg, C., Sunderkotter, C., Roth, J., 2007. Glucocorticoids induce
differentiation of a speciﬁcally activated, anti-inﬂammatory subtype of human
monocytes. Blood 109, 1265–1274.
lmore, S.W., Pratt, J.K., Coghlan, M.J., Mao, Y., Green, B.E., Anderson, D.D., Stashko,
M.A., Lin, C.W., Falls, D., Nakane, M., Miller, L., Tyree, C.M., Miner, J.N., Lane, B.,
2004.Differentiationof in vitro transcriptional repressionandactivationproﬁles
of selective glucocorticoid modulators. Bioorg. Med. Chem. Lett. 14, 1721–1727.
rgang, P., Leden, P., Bryndova, J., Zbankova, S., Miksik, I., Kment, M., Pacha, J.,
2007. Glucocorticoid availability in colonic inﬂammation of rat. Dig. Dis. Sci.
53, 2160–2167.
adok, V.A., Bratton, D.L., Konowal, A., Freed, P.W.,Westcott, J.Y., Henson, P.M., 1998.
Macrophages that have ingested apoptotic cells in vitro inhibit proinﬂammatory
cytokine production through autocrine/paracrine mechanisms involving TGF-
PGE2, and PAF. J. Clin. Invest. 101, 890–898.
inotto, S., Krieglstein, K., Schober, A., Deimling, F., Lindner, K., Bruhl, B., Beier, K.,
Metz, J., GarciaArraras, J.E., RoigLopez, J.L., Monaghan, P., Schmid, W., Cole, T.J.,
Kellendonk, C., Tronche, F., Schutz, G., Unsicker, K., 1999. Analysis of mice car-
rying targeted mutations of the glucocorticoid receptor gene argues against
an essential role of glucocorticoid signalling for generating adrenal chromafﬁn
cells. Development 126, 2935–2944.
iore, C., Nardi, A., Dalla Valle, L., Pellati, D., Krozowski, Z., Colombo, L., Armanini,
D., 2009. Identiﬁcation of the 11-hydroxysteroid dehydrogenase type 1 mRNA
and protein in human mononuclear leukocytes. Exp. Clin. Endocrinol. Diabetes
117, 514–518.
rank,M.G.,Miguel, Z.D.,Watkins, L.R.,Maier, S.F., 2010. Prior exposure toglucocorti-
coids sensitizes the neuroinﬂammatory and peripheral inﬂammatory responses
to E. coli lipopolysaccharide. Brain Behav. Immun. 24, 19–30.reeman, L., Hewison, M., Hughes, S.V., Evans, K.N., Hardie, D., Means, T.K.,
Chakraverty, R., 2005. Expression of 11-hydroxysteroid dehydrogenase type
1 permits regulation of glucocorticoid bioavailability by human dendritic cells.
Blood 106, 2042–2049.
under, J.W., 1997. Glucocorticoid and mineralocorticoid receptors: Biology and
clinical relevance. Annu. Rev. Med. 48, 231–240.ellular Endocrinology 335 (2011) 2–13
Giles, K.M., Ross, K., Rossi, A.G., Hotchin, N.A., Haslett, C., Dransﬁeld, I., 2001. Gluco-
corticoid augmentation of macrophage capacity for phagocytosis of apoptotic
cells is associated with reduced p130Cas expression, loss of paxillin/pyk2 phos-
phorylation, and high levels of active Rac. J. Immunol. 167, 976–986.
Gilmour, J.S., Coutinho, A.E., Cailhier, J.F., Man, T.Y., Clay, M., Thomas, G., Harris,
H.J., Mullins, J.J., Seckl, J.R., Savill, J.S., Chapman, K.E., 2006. Local ampliﬁca-
tion of glucocorticoids by 11-hydroxysteroid dehydrogenase type 1 promotes
macrophage phagocytosis of apoptotic leukocytes. J. Immunol. 176, 7605–7611.
Gilroy, D.W., 2004. The endogenous control of acute inﬂammation - from onset to
resolution. Drug Discov. Today: Therap. Strategies 1, 313.
Godfrey, D.I., Purton, J.F., Boyd, R.L., Cole, T.J., 2001. Glucocorticoids and the thymus:
the view from the middle of the road. Trends Immunol. 22, 243.
Gotoh, T., Chowdhury, S., Takiguchi, M., Mori, M., 1997. The glucocorticoid-
responsive gene cascade: activation of the rat arginase gene through induction
of C/EBP. J. Biol. Chem. 272, 3694–3698.
Goulding, N.J., Godolphin, J.L., Sampson, M.B., Maddison, P.J., Flower, R.J., 1990.
Hydrocortisone induces lipocortin 1 production by peripheral blood mononu-
clear cells in vivo in man. Biochem. Soc. Trans. 18, 306–307.
Gout, J., Tirard, J., Thevenon, C., Riou, J.P., Begeot, M., Naville, D., 2006.
CCAAT/enhancer-binding proteins (C/EBPs) regulate the basal and cAMP-
induced transcription of the human 11-hydroxysteroid dehydrogenase
encoding gene in adipose cells. Biochimie 88, 1115–1124.
Grange, T., Cappabianca, L., Flavin, M., Sassi, H., Thomassin, H., 2001. In vivo analysis
of the model tyrosine aminotransferase gene reveals multiple sequential steps
in glucocorticoid receptor action. Oncogene 20, 3028–3038.
Grange, T., Roux, J., Rigaud, G., Pictet, R., 1989. Two remote glucocorticoid responsive
units interact cooperatively to promote glucocorticoid induction of rat tyrosine
aminotransferase gene expression. Nucl. Acids Res. 17, 8695–8709.
Grange, T., Roux, J., Rigaud, G., Pictet, R., 1991. Cell-type speciﬁc activity of two glu-
cocorticoid responsive units of rat tyrosine aminotransferase gene is associated
with multiple binding sites for C/EBP and a novel liver-speciﬁc nuclear factor.
Nucl. Acids Res. 19, 131–139.
Haas, C.S., Creighton, C.J., Pi, X., Maine, I., Koch, A.E., Haines, G.K., Ling, S., Chinnaiyan,
A.M., Holoshitz, J., 2006. Identiﬁcation of genesmodulated in rheumatoid arthri-
tis using complementaryDNAmicroarray analysis of lymphoblastoid B cell lines
from disease-discordant monozygotic twins. Arthritis Rheum. 54, 2047–2060.
Hager, G.L., Nagaich, A.K., Johnson, T.A., Walker, D.A., John, S., 2004. Dynamics of
nuclear receptor movement and transcription. Biochim. Biophys. Acta 1677,
46–51.
Hamdi, H., Godot, V., Maillot, M.C., Prejean, M.V., Cohen, N., Krzysiek, R., Lemoine,
F.M., Zou,W., Emilie,D., 2007. Inductionof antigen-speciﬁc regulatoryT lympho-
cytes by human dendritic cells expressing the glucocorticoid-induced leucine
zipper. Blood 110, 211–219.
Hammer, M., Mages, J., Dietrich, H., Servatius, A., Howells, N., Cato, A.C., Lang, R.,
2006. Dual speciﬁcity phosphatase 1 (DUSP1) regulates a subset of LPS-induced
genes and protects mice from lethal endotoxin shock. J. Exp. Med. 203, 15–20.
Hannon, R., Croxtall, J.D., Getting, S.J., Roviezzo, F., Yona, S., Paul-Clark, M.J., Gavins,
F.N., Perretti,M.,Morris, J.F., Buckingham, J.C., Flower,R.J., 2003.Aberrant inﬂam-
mation and resistance to glucocorticoids in annexin 1−/− mouse. FASEB J. 17,
253–255.
Härd, T., Kellenbach, E., Boelens, R., Maler, B.A., Dahlman, K., Freedman, L.P.,
Carlstedt-Duke, J., Yamamoto, K.R., Gustafsson, J.-Å., 1990. Solution structure
of the glucocorticoid receptor DNA-binding domain. Science 249, 157–160.
Hardy, R.S., Rabbitt, E.H., Filer, A., Emery, P., Hewison, M., Stewart, P.M., Gittoes,
N., Buckley, C.D., Raza, K., Cooper, M.S., 2008. Local and systemic glucocorticoid
metabolism in inﬂammatory arthritis. Ann. Rheum. Dis. 67, 1204–1210.
Harizi, H., Mormede, P., Corcuff, J.B., 2008. Inter-strain differences in glucocorticoid
andmineralocorticoid effects onmacrophage and lymphocyte functions inmice.
J. Neuroimmunol. 204, 38–42.
Haslett, C., Lee,A., Savill, J.S.,Meagher, L.,Whyte,M.K., 1991.Apoptosis (programmed
cell death) and functional changes in aging neutrophils: modulation by inﬂam-
matory mediators. Chest 99, 6S.
Hawes, A.S., Richardson, R.P., Antonacci, A.C., Calvano, S.E., 1995. Chronic patho-
physiologic elevation of corticosterone after thermal injury or thermal injury
and burn wound infection adversely affects body mass, lymphocyte numbers,
and outcome. J. Burn Care Rehabil. 16, 1–15.
Hawrylowicz, C.M., 2005. Regulatory T cells and IL-10 in allergic inﬂammation. J.
Exp. Med. 202, 1459–1463.
Heasman, S.J., Giles, K.M., Ward, C., Rossi, A.G., Haslett, C., Dransﬁeld, I., 2003.
Glucocorticoid-mediated regulation of granulocyte apoptosis and macrophage
phagocytosis of apoptotic cells: implications for the resolution of inﬂammation.
J. Endocrinol. 178, 29–36.
Heck, S., Bender, K., Kullmann, M., Gottlicher, M., Herrlich, P., Cato, A.C., 1997.
IB-independent downregulation ofNF-B activity by glucocorticoid receptor.
EMBO J. 16, 4698–4707.
Heck, S., Kullmann, M., Gast, A., Ponta, H., Rahmsdorf, H.J., Herrlich, P., Cato, A.C.B.,
1994. A distinctmodulating domain in glucocorticoid receptormonomers in the
repression of activity of the transcription factor AP-1. EMBO J. 13, 4087–4095.
Hennebold, J.D., Ryu, S.Y., Mu, H.H., Galbraith, A., Daynes, R.A., 1996. 11-
hydroxysteroid dehydrogenase modulation of glucocorticoid activities in
lymphoid organs. Am. J. Physiol. 270, R1296–1306.
Hermanowski-Vosatka, A., Balkovec, J.M., Cheng, K., Chen, H.Y., Hernandez, M., Koo,
G.C., Le Grand, C.B., Li, Z., Metzger, J.M., Mundt, S.S., Noonan, H., Nunes, C.N.,
Olson, S.H., Pikounis, B., Ren, N., Robertson, N., Schaeffer, J.M., Shah, K., Springer,
M.S., Strack, A.M., Strowski, M., Wu, K., Wu, T., Xiao, J., Zhang, B.B., Wright,
S.D., Thieringer, R., 2005. 11®-HSD1 inhibition amelioratesmetabolic syndrome
r and C
H
H
H
H
H
I
I
I
J
J
J
J
J
J
J
K
K
K
K
K
K
K
K
K
L
L
L
LA.E. Coutinho, K.E. Chapman / Molecula
and prevents progression of atherosclerosis in mice. J. Exp. Med. 202, 517–
527.
erold, M.J., McPherson, K.G., Reichardt, H.M., 2006. Glucocorticoids in T cell apop-
tosis and function. Cell. Mol. Life Sci. 63, 60–72.
ollenberg, S.M., Weinberger, C., Ong, E.S., Cerelli, G., Oro, A., Lebo, R., Thompson,
E.B., Rosenfeld, M.G., Evans, R.M., 1985. Primary structure and expression of a
functional human glucocorticoid receptor cDNA. Nature 318, 635–641.
orie-Inoue, K., Takayama, K., Bono, H.U., Ouchi, Y., Okazaki, Y., Inoue, S., 2006.
Identiﬁcation of novel steroid target genes through the combination of bioin-
formatics and functional analysis of hormone response elements. Biochem.
Biophys. Res. Commun. 339, 99–106.
u, B., Ullenbruch, M.R., Jin, H., Gharaee-Kermani, M., Phan, S.H., 2007. An essential
role for CCAAT/enhancer binding protein  in bleomycin-induced pulmonary
ﬁbrosis. J. Pathol. 211, 455–462.
uggins, A., Paschalidis, N., Flower, R.J., Perretti, M., D’Acquisto, F., 2009. Annexin-
1-deﬁcient dendritic cells acquire a mature phenotype during differentiation.
Faseb J. 23, 985–996.
gnatova, I.D., Kostadinova, R.M., Goldring, C.E., Nawrocki, A.R., Frey, F.J., Frey, B.M.,
2009. Tumor necrosis factor-〈 upregulates 11-hydroxysteroid dehydrogenase
type 1 expression by CCAAT/enhancer binding protein- in HepG2 cells. Am. J.
Physiol. Endocrinol. Metab. 296, E367–377.
mai, E., Stromstedt, P.E., Quinn, P.G., Carlstedtduke, J., Gustafsson, J.A., Granner,
D.K., 1990. Characterization of a complex glucocorticoid response unit in the
phosphoenolpyruvate carboxykinase gene. Mol. Cell. Biol. 10, 4712–4719.
to, Y., Daitoku, H., Fukamizu, A., 2009. Foxo1 increases pro-inﬂammatory gene
expression by inducing C/EBP in TNF-treated adipocytes. Biochem. Biophys.
Res. Commun. 378, 290–295.
affe, H.L., 1924. The inﬂuence of the suprarenal gland on the thymus. J. Exp. Med.,
XL, 325–343.
ang, C., Obeyesekere, V.R., Alford, F.P., Inder, W.J., 2009. Skeletal muscle 11-
hydroxysteroid dehydrogenase type 1 activity is upregulated following elective
abdominal surgery. Eur. J. Endocrinol. 160, 249–255.
ohansson Haque, K., Palanichamy, E., Okret, S., 2008. Stimulation of MAPK-
phospatase 1 (MKP-1) gene expression by glucocorticoids occurs through a
tethering mechanism involving C/EBP. J. Mol. Endocrinol. 41, 239–249.
ohn, S., Johnson, T.A., Sung, M.H., Biddie, S.C., Trump, S., Koch-Paiz, C.A., Davis,
S.R., Walker, R., Meltzer, P.S., Hager, G.L., 2009. Kinetic complexity of the global
response to glucocorticoid receptor action. Endocrinology 150, 1766–1774.
ohn, S., Sabo, P.J., Johnson, T.A., Sung, M.H., Biddie, S.C., Lightman, S.L., Voss, T.C.,
Davis, S.R., Meltzer, P.S., Stamatoyannopoulos, J.A., Hager, G.L., 2008. Interac-
tion of the glucocorticoid receptor with the chromatin landscape. Mol. Cell. 29,
611–624.
onat, C., Rahmsdorf, H.J., Park, K.K., Cato, A.C.B., Gebel, S., Ponta, H., Herrlich, P.,
1990. Antitumor promotion and antiinﬂammation: down-modulation of AP-1
(Fos Jun) activity by glucocorticoid hormone. Cell 62, 1189–1204.
ondal, M., Pazirandeh, A., Okret, S., 2004. Different roles for glucocorticoids in thy-
mocyte homeostasis? Trends Immunol. 25, 595–600.
ardon, T., Senesi, S., Marcolongo, P., Legeza, B., Banhegyi, G., Mandl, J., Fulceri, R.,
Benedetti, A., 2008. Maintenance of luminal NADPH in the endoplasmic retic-
ulum promotes the survival of human neutrophil granulocytes. FEBS Lett. 582,
1809–1815.
arin, M., 1998. New twists in gene regulation by glucocorticoid receptor: Is DNA
binding dispensable? Cell 93, 487–490.
assel, O., Cato, A.C., 2002. Mast cells as targets for glucocorticoids in the treatment
of allergic disorders. Ernst Schering Res. Found Workshop, 153–176.
imura, T., Chowdhury, S., Tanaka, T., Shimizu, A., Iwase, K., Oyadomari, S., Gotoh, T.,
Matsuzaki, H., Mori, M., Akira, S., Takiguchi, M., 2001. CCAAT/enhancer-binding
protein  is required for activation of genes for ornithine cycle enzymes by
glucocorticoids and glucagon in primary- cultured hepatocytes. FEBS Lett. 494,
105–111.
ing, L.B., Vacchio, M.S., Dixon, K., Hunziker, R., Margulies, D.H., Ashwell, J.D., 1995.
A targeted glucocorticoid receptor antisense transgene increases thymocyte
apoptosis and alters thymocyte development. Immunity 3, 647–656.
izaki, T., Ookawara, T., Oh-Ishi, S., Itoh, Y., Iwabuchi, K., Onoe, K., Day, N.K., Good,
R.A., Ohno, H., 1998. An increase in basal glucocorticoid concentration with age
induces suppressor macrophages with high-density Fc gamma RII/III. Immunol-
ogy 93, 409–414.
leiman, A., Tuckermann, J.P., 2007. Glucocorticoid receptor action in beneﬁcial and
side effects of steroid therapy: lessons from conditional knockout mice. Mol.
Cell. Endocrinol. 275, 98–108.
oldzic-Zivanovic, N., Tu, H., Juelich, T.L., Rady, P.L., Tyring, S.K., Hudnall, S.D.,
Smith, E.M., Hughes, T.K., 2006. Regulation of adrenal glucocorticoid synthe-
sis by interleukin-10: a preponderance of IL-10 receptor in the adrenal zona
fasciculata. Brain Behav. Immun. 20, 460–468.
uhn, R., Lohler, J., Rennick, D., Rajewsky, K., Muller, W., 1993. Interleukin-10-
deﬁcient mice develop chronic enterocolitis. Cell 75, 263–274.
acy-Hulbert, A., Smith, A.M., Tissire, H., Barry, M., Crowley, D., Bronson, R.T., Roes,
J.T., Savill, J.S., Hynes, R.O., 2007. Ulcerative colitis and autoimmunity induced by
loss of myeloid alphav integrins. Proc. Natl. Acad. Sci. U.S.A. 104, 15823–15828.
efstin, J.A., Yamamoto, K.R., 1998. Allosteric effects of DNA on transcriptional reg-
ulators. Nature 392, 885–888.
ightman, S.L., 2008. The neuroendocrinology of stress: a never ending story. J.
Neuroendocrinol. 20, 880–884.
im, H.Y., Muller, N., Herold, M.J., van den Brandt, J., Reichardt, H.M., 2007. Gluco-
corticoids exert opposing effects on macrophage function dependent on their
concentration. Immunology 122, 47–53.ellular Endocrinology 335 (2011) 2–13 11
Limbourg, F.P., Huang, Z., Plumier, J.C., Simoncini, T., Fujioka, M., Tuckermann, J.,
Schutz, G., Moskowitz, M.A., Liao, J.K., 2002. Rapid nontranscriptional activation
of endothelial nitric oxide synthase mediates increased cerebral blood ﬂow and
stroke protection by corticosteroids. J. Clin. Invest. 110, 1729–1738.
Lu, F.W., Yasutomo,K., Goodman,G.B.,McHeyzer-Williams, L.J.,McHeyzer-Williams,
M.G., Germain, R.N., Ashwell, J.D., 2000. Thymocyte resistance to glucocorticoids
leads to antigen-speciﬁc unresponsiveness due to “holes” in the T cell repertoire.
Immunity 12, 183–192.
Luisi, B.F., Xu,W.X., Otwinowski, Z., Freedman, L.P., Yamamoto, K.R., Sigler, P.B., 1991.
Crystallographic analysis of the interaction of the glucocorticoid receptor With
DNA. Nature 352, 497–505.
Luther, C., Adamopoulou, E., Stoeckle, C., Brucklacher-Waldert, V., Rosenkranz, D.,
Stoltze, L., Lauer, S., Poeschel, S., Melms, A., Tolosa, E., 2009. Prednisolone treat-
ment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia
gravis patients. J. Immunol. 183, 841–848.
Madauss, K.P., Bledsoe, R.K., McLay, I., Stewart, E.L., Uings, I.J., Weingarten, G.,
Williams, S.P., 2008. The ﬁrst X-ray crystal structure of the glucocorticoid
receptor bound to a non-steroidal agonist. Bioorg. Med. Chem. Lett. 18, 6097–
6099.
Maderna, P., Yona, S., Perretti, M., Godson, C., 2005. Modulation of phagocy-
tosis of apoptotic neutrophils by supernatant from dexamethasone-treated
macrophages and annexin-derived peptide Ac(2-26). J. Immunol. 174,
3727–3733.
Maier, J.V., Brema, S., Tuckermann, J., Herzer, U., Klein, M., Stassen, M., Moor-
thy, A., Cato, A.C., 2007. Dual speciﬁcity phosphatase 1 knockout mice show
enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids. Mol.
Endocrinol. 21, 2663–2671.
Martinez, F.O., Gordon, S., Locati, M., Mantovani, A., 2006. Transcriptional proﬁl-
ing of the human monocyte-to-macrophage differentiation and polarization:
new molecules and patterns of gene expression. J. Immunol. 177, 7303–
7311.
McColl, A., Bournazos, S., Franz, S., Perretti, M., Morgan, B.P., Haslett, C., Dransﬁeld,
I., 2009. Glucocorticoids induce protein S-dependent phagocytosis of apoptotic
neutrophils by human macrophages. J. Immunol. 183, 2167–2175.
McColl, A., Michlewska, S., Dransﬁeld, I., Rossi, A.G., 2007. Effects of glucocorticoids
on apoptosis and clearance of apoptotic cells. Sci. W. J. 7, 1165–1181.
McEwen, B.S., Biron, C.A., Brunson, K.W., Bulloch, K., Chambers, W.H., Dhabhar, F.S.,
Goldfarb, R.H., Kitson, R.P., Miller, A.H., Spencer, R.L., Weiss, J.M., 1997. The role
of adrenocorticoids as modulators of immune function in health and disease:
neural, endocrine and immune interactions. Brain Res. Rev. 23, 79–133.
McKay, L.I., Cidlowski, J.A., 1999. Molecular control of immune/inﬂammatory
responses: Interactions between NF-B and steroid receptor-signaling path-
ways. Endocrinol. Rev. 20, 435–459.
McKnight, S.L., 2001. McBindall—a better name for CCAAT/enhancer binding pro-
teins? Cell 107, 259–261.
Meijsing, S.H., Pufall, M.A., So, A.Y., Bates, D.L., Chen, L., Yamamoto, K.R., 2009. DNA
binding site sequence directs glucocorticoid receptor structure and activity. Sci-
ence 324, 407–410.
Miesfeld, R., Rusconi, S., Godowski, P.J.,Maler, B.A., Okret, S.,Wikström, A.C., Gustafs-
son, J.-Å., Yamamoto, K.R., 1986. Genetic complementation of a glucocorticoid
receptor deﬁciency by expression of cloned receptor cDNA. Cell 46, 389–399.
Miller, A.H., Spencer, R.L., Stein, M., McEwen, B.S., 1990. Adrenal steroid receptor
binding in spleen and thymus after stress or dexamethasone. Am. J. Physiol.
259, E405–E412.
Millward, C.A., Heaney, J.D., Sinasac, D.S., Chu, E.C., Bederman, I.R., Gilge, D.A., Previs,
S.F., Croniger, C.M., 2007. Mice with a deletion in the gene for CCAAT/enhancer-
binding protein  are protected against diet-induced obesity. Diabetes 56,
161–167.
Mozo, L., Suarez, A., Gutierrez, C., 2004. Glucocorticoids up-regulate constitutive
interleukin-10 production by human monocytes. Clin. Exp. Allergy 34, 406–
412.
Munck, A., Guyre, P.M., Holbrook, N.J., 1984. Physiological functions of glucocor-
ticoids in stress and their relationship to pharmacological actions. Endocrinol.
Rev. 5, 25–44.
Muzikar, K.A., Nickols, N.G., Dervan, P.B., 2009. Repression of DNA-binding depen-
dent glucocorticoid receptor-mediated gene expression. Proc. Natl. Acad. Sci.
U.S.A. 106, 16598–16603.
Necela, B.M., Cidlowski, J.A., 2004. Mechanisms of glucocorticoid receptor action in
noninﬂammatory and inﬂammatory cells. Proc. Am. Thorac. Soc. 1, 239–246.
Nerlov, C., 2007. The C/EBP family of transcription factors: a paradigm for inter-
action between gene expression and proliferation control. Trends Cell Biol. 17,
318–324.
Newton,R.,Holden,N.S., 2007. Separating transrepressionand transactivation: adis-
tressing divorce for the glucocorticoid receptor? Mol. Pharmacol. 72, 799–809.
O’Sullivan, B.J., Thomas, R., 2002. CD40 Ligation conditions dendritic cell antigen-
presenting function through sustained activation of NF-B. J. Immunol. 168,
5491–5498.
Olsen, N., Sokka, T., Seehorn, C.L., Kraft, B., Maas, K., Moore, J., Aune, T.M., 2004. A
gene expression signature for recent onset rheumatoid arthritis in peripheral
blood mononuclear cells. Ann. Rheum. Dis. 63, 1387–1392.Payne, V.A., Au, W.S., Gray, S.L., Nora, E.D., Rahman, S.M., Sanders, R., Hadaschik, D.,
Friedman, J.E., O’Rahilly, S., Rochford, J.J., 2007. Sequential regulation of diacyl-
glycerol acyltransferase 2 expression by CAAT/enhancer-binding protein beta
(C/EBP) and C/EBP during adipogenesis. J. Biol. Chem. 282, 21005–21014.
Payvar, F., Defranco, D., Firestone, G.L., Edgar, B., Wrange, O., Okret, S., Gustafsson,
J.A., Yamamoto, K.R., 1983. Sequence-speciﬁc binding of glucocorticoid receptor
1 and C
P
P
P
P
P
P
P
P
P
P
P
R
R
R
R
R
R
R
R
R
R
R
R
R
S
S
S2 A.E. Coutinho, K.E. Chapman / Molecular
to MTV DNA at sites within and upstream of the transcribed region. Cell 35,
381–392.
azirandeh, A., Jondal, M., Okret, S., 2005. Conditional expression of a glucocorticoid
receptor transgene in thymocytes reveals a role for thymic-derived glucocorti-
coids in thymopoiesis in vivo. Endocrinology 146, 2501–2507.
azirandeh, A., Xue, Y., Prestegaard, T., Jondal, M., Okret, S., 2002. Effects of altered
glucocorticoid sensitivity in the T-cell lineage on thymocyte and T-cell home-
ostasis. FASEB J. 16, 727–729.
earce, D., Yamamoto, K.R., 1993. Mineralocorticoid and glucocorticoid receptor
activities distinguishedbynonreceptor factors at a composite response element.
Science 259, 1161–1165.
enner, G., Gang, G., Sun, X., Wray, C., Hasselgren, P.O., 2002. C/EBP DNA-
binding activity is upregulated by a glucocorticoid-dependent mechanism
in septic muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282, R439–
444.
epin, M.-C., Pothier, F., Barden, N., 1992. Impaired type II glucocorticoid recep-
tor function in mice bearing antisense RNA transgene. Nature 355, 725–
728.
erretti, M., Ahluwalia, A., 2000. The microcirculation and inﬂammation: site of
action for glucocorticoids. Microcirculation 7, 147–161.
erretti, M., D’Acquisto, F., 2009. Annexin A1 and glucocorticoids as effectors of the
resolution of inﬂammation. Nat. Rev. Immunol. 9, 62–70.
laney, S.L., Litwack, G., 2000. Glucocorticoid-induced apoptosis in lymphocytes.
Biochem. Biophys. Res. Commun. 279, 307–312.
urton, J.F., Boyd, R.L., Cole, T.J., Godfrey, D.I., 2000. Intrathymic T cell develop-
ment and selection proceeds normally in the absence of glucocorticoid receptor
signaling. Immunity 13, 179–186.
urton, J.F., Monk, J.A., Liddicoat, D.R., Kyparissoudis, K., Sakkal, S., Richardson, S.J.,
Godfrey, D.I., Cole, T.J., 2004. Expression of the glucocorticoid receptor from the
1Apromoter correlateswith T lymphocyte sensitivity to glucocorticoid-induced
cell death. J. Immunol. 173, 3816–3824.
urton, J.F., Zhan, Y., Liddicoat, D.R., Hardy, C.L., Lew, A.M., Cole, T.J., Godfrey, D.I.,
2002. Glucocorticoid receptor deﬁcient thymic and peripheral T cells develop
normally in adult mice. Eur. J. Immunol. 32, 3546–3555.
ea, D., van Kooten, C., van Meijgaarden, K.E., Ottenhoff, T.H., Melief, C.J., Offringa,
R., 2000. Glucocorticoids transform CD40-triggering of dendritic cells into an
alternative activation pathway resulting in antigen-presenting cells that secrete
IL-10. Blood 95, 3162–3167.
eddy, T.E., Pauli, F., Sprouse,R.O.,Neff,N.F.,Newberry,K.M.,Garabedian,M.J.,Myers,
R.M., 2009. Genomic determination of the glucocorticoid response reveals unex-
pected mechanisms of gene regulation. Genome Res. 19, 2163–2171.
eichardt, H.M., Kaestner, K.H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass,
P., Schmid, W., Herrlich, P., Angel, P., Schütz, G., 1998. DNA binding of the glu-
cocorticoid receptor is not essential for survival. Cell 93, 531–541.
eichardt, H.M., Tuckermann, J.P., Gottlicher, M., Vujic, M., Weih, F., Angel, P., Her-
rlich, P., Schutz, G., 2001. Repression of inﬂammatory responses in the absence
of DNA binding by the glucocorticoid receptor. EMBO J. 20, 7168–7173.
eichardt, H.M., Umland, T., Bauer, A., Kretz, O., Schütz, G., 2000. Mice with an
increased glucocorticoid receptor gene dosage show enhanced resistance to
stress and endotoxic shock. Mol. Cell. Biol. 20, 9009–9017.
ennick, D., Davidson, N., Berg, D., 1995. Interleukin-10 gene knock-out mice: a
model of chronic inﬂammation. Clin. Immunol. Immunopathol. 76, S174–S178.
hen, T., Cidlowski, J.A., 2005. Antiinﬂammatory action of glucocorticoids - new
mechanisms for old drugs. N. Engl. J. Med. 353, 1711–1723.
ichards, D.F., Fernandez, M., Caulﬁeld, J., Hawrylowicz, C.M., 2000. Glucocorticoids
drive human CD8(+) T cell differentiation towards a phenotype with high IL-10
and reduced IL-4 IL-5 and IL-13 production. Eur. J. Immunol. 30, 2344–2354.
ogatsky, I., Wang, J.C., Derynck, M.K., Nonaka, D.F., Khodabakhsh, D.B., Haqq, C.M.,
Darimont, B.D., Garabedian, M.J., Yamamoto, K.R., 2003. Target-speciﬁc utiliza-
tion of transcriptional regulatory surfaces by the glucocorticoid receptor. Proc.
Natl. Acad. Sci. U.S.A. 100, 13845–13850.
ook, G.A., Hernandez-Pando, R., Lightman, S.L., 1994. Hormones, peripherally acti-
vated prohormones and regulation of the Th1/Th2 balance. Immunol. Today 15,
301–303.
osenstock, J., Banarer, S., Fonseca, V., Inzucchi, S., Holllis, G., Flores, R., Levy, R.,
Williams, B., Huber, R., 2009. Efﬁcacy and safety of the 11-HSD1 inhibitor,
INCB13739, added to metformin therapy in patients with type 2 diabetes,
Abstracts of the 69th Meeting of the American Diabetes Association, New
Orleans, 7-LB.
uffell, D., Mourkioti, F., Gambardella, A., Kirstetter, P., Lopez, R.G., Rosenthal, N.,
Nerlov, C., 2009. A CREB-C/EBP cascade induces M2 macrophage-speciﬁc gene
expression and promotes muscle injury repair. Proc. Natl. Acad. Sci. U.S.A. 106,
17475–17480.
utella, S., Lemoli, R.M., 2004. Regulatory T cells and tolerogenic dendritic cells: from
basic biology to clinical applications. Immunol. Lett. 94, 11–26.
ai, S., Esteves, C.L., Kelly, V., Michailidou, Z., Anderson, K., Coll, A.P., Nakagawa,
Y., Ohzeki, T., Seckl, J.R., Chapman, K.E., 2008. Glucocorticoid regulation of the
promoter of 11-hydroxysteroid dehydrogenase type 1 is indirect and requires
C/EBP. Mol. Endocrinol. 22, 2049–2060.
ai, S., Nakagawa, Y., Sakaguchi, K., Okada, S., Takahashi, H., Hongo, T., Seckl, J.R.,
Chapman, K.E., Ohzeki, T., 2009. Differential regulation of 11-hydroxysteroid
dehydrogenase-1 by dexamethasone in glucocorticoid-sensitive and -resistant
childhood lymphoblastic leukemia. Leuk. Res. 33, 1696–1698.
alojin, K.V., Owusu, I.B., Millerchip, K.A., Potter, M., Platt, K.A., Oravecz, T., 2006.
Essential role of MAPK phosphatase-1 in the negative control of innate immune
responses. J. Immunol. 176, 1899–1907.ellular Endocrinology 335 (2011) 2–13
Savill, J., Dransﬁeld, I., Gregory, C., Haslett, C., 2002. A blast from the past: clearance
of apoptotic cells regulates immune responses. Nat. Rev. Immunol. 2, 965–975.
Savoldi, G., Fenaroli, A., Ferrari, F., Rigaud, G., Albertini, A., Di Lorenzo, D., 1997.
The glucocorticoid receptor regulates the binding of C/EBP on the 1-acid
glycoprotein promoter in vivo. DNA Cell Biol. 16, 1467–1476.
Schacke, H., Berger, M., Rehwinkel, H., Asadullah, K., 2007. Selective glucocorticoid
receptor agonists (SEGRAs): novel ligands with an improved therapeutic index.
Mol. Cell. Endocrinol. 275, 109–117.
Scheinman, R.I., Cogswell, P.C., Lofquist, A.K., Baldwin, A.S., 1995. Role of transcrip-
tional activationof IB inmediationof immunosuppressionbyglucocorticoids.
Science 270, 283–286.
Schmidt, M., Weidler, C., Naumann, H., Anders, S., Scholmerich, J., Straub, R.H., 2005.
Reduced capacity for the reactivation of glucocorticoids in rheumatoid arthri-
tis synovial cells: Possible role of the sympathetic nervous system? Arthritis
Rheum. 52, 1711–1720.
Schroeder-Gloeckler, J.M., Rahman, S.M., Janssen, R.C., Qiao, L., Shao, J., Roper, M.,
Fischer, S.J., Lowe, E., Orlicky, D.J., McManaman, J.L., Palmer, C., Gitomer, W.L.,
Huang, W., O’Doherty, R.M., Becker, T.C., Klemm, D.J., Jensen, D.R., Pulawa, L.K.,
Eckel, R.H., Friedman, J.E., 2007. CCAAT/enhancer-binding protein- deletion
reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice. J. Biol.
Chem. 282, 15717–15729.
Seckl, J.R., 2000. 11-hydroxysteroid dehydrogenases. Encyclopedia Stress 2,
413–421.
Seckl, J.R.,Morton, N.M., Chapman, K.E.,Walker, B.R., 2004. Glucocorticoids and11-
hydroxysteroid dehydrogenase in adipose tissue. Recent Prog. Horm. Res. 59,
359–393.
Serhan, C.N., Savill, J., 2005. Resolution of inﬂammation: the beginning programs
the end. Nat. Immunol. 6, 1191–1197.
Shanks, N., Windle, R.J., Perks, P.A., Harbuz, M.S., Jessop, D.S., Ingram, C.D., Lightman,
S.L., 2000. Early-life exposure to endotoxin alters hypothalamic-pituitary-
adrenal function and predisposition to inﬂammation. Proc. Natl. Acad. Sci. U.S.A.
97, 5645–5650.
Sica, A., Bronte, V., 2007. Altered macrophage differentiation and immune dysfunc-
tion in tumor development. J. Clin. Invest. 117, 1155–1166.
Simons Jr, S.S., 2008. What goes on behind closed doors: physiological versus phar-
macological steroid hormone actions. Bioessays 30, 744–756.
Smoak, K.A., Cidlowski, J.A., 2004. Mechanisms of glucocorticoid receptor signaling
during inﬂammation. Mech. Ageing Dev. 125, 697–706.
So, A.Y., Chaivorapol, C., Bolton, E.C., Li, H., Yamamoto, K.R., 2007. Determinants of
cell- and gene-speciﬁc transcriptional regulation by the glucocorticoid receptor.
PLoS Genet. 3, e94.
So, A.Y., Cooper, S.B., Feldman, B.J., Manuchehri, M., Yamamoto, K.R., 2008. Conser-
vation analysis predicts in vivo occupancy of glucocorticoid receptor-binding
sequences at glucocorticoid-induced genes. Proc. Natl. Acad. Sci. U.S.A. 105,
5745–5749.
Solito, E., Mulla, A., Morris, J.F., Christian, H.C., Flower, R.J., Buckingham, J.C., 2003.
Dexamethasone induces rapid serine-phosphorylation and membrane translo-
cation of annexin 1 in a human folliculostellate cell line via a novel nongenomic
mechanism involving the glucocorticoid receptor, protein kinase C, phos-
phatidylinositol 3-kinase, and mitogen-activated protein kinase. Endocrinology
144, 1164–1174.
Sorrells, S.F., Caso, J.R., Munhoz, C.D., Sapolsky, R.M., 2009. The stressed CNS: when
glucocorticoids aggravate inﬂammation. Neuron 64, 33–39.
Souverein, P.C., Berard, A., Van Staa, T.P., Cooper, C., Egberts, A.C.G., Leufkens, H.G.M.,
Walker, B.R., 2004. Use of oral glucocorticoids and risk of cardiovascular and
cerebrovascular disease in a population based case-control study. Heart 90,
859–865.
Staiger, J., Lueben, M.J., Berrigan, D., Malik, R., Perkins, S.N., Hursting, S.D., John-
son, P.F., 2008. C/EBP regulates body composition, energy balance-related
hormones, and tumor growth. Carcinogenesis 30, 832–840.
Stavreva, D.A., Wiench, M., John, S., Conway-Campbell, B.L., McKenna, M.A., Poo-
ley, J.R., Johnson, T.A., Voss, T.C., Lightman, S.L., Hager, G.L., 2009. Ultradian
hormone stimulation induces glucocorticoid receptor-mediated pulses of gene
transcription. Nat. Cell Biol. 11, 1093–1102.
Stellato, C., 2004. Post-transcriptional and nongenomic effects of glucocorticoids.
Proc. Am. Thorac. Soc. 1, 255–263.
Sternberg, E.M., 2006. Neural regulation of innate immunity: a coordinated nonspe-
ciﬁc host response to pathogens. Nat. Rev. Immunol. 6, 318–328.
Tchen, C.R., Martins, J.R., Paktiawal, N., Perelli, R., Saklatvala, J., Clark, A.R., 2009.
Glucocorticoid regulation of mouse and human dual speciﬁcity phosphatase
1 (DUSP1) genes: unusual cis-acting elements and unexpected evolutionary
divergence. J. Biol. Chem. (November (23)), Epub ahead of print.
Thieringer, R., Le Grand, C.B., Carbin, L., Cai, T.Q., Wong, B., Wright, S.D.,
Hermanowski-Vosatka, A., 2001. 11-Hydroxysteroid dehydrogenase type 1 is
induced in human monocytes upon differentiation to macrophages. J. Immunol.
167, 30–35.
Tuckermann, J.P., Kleiman, A., McPherson, K.G., Reichardt, H.M., 2005. Molecular
mechanisms of glucocorticoids in the control of inﬂammation and lymphocyte
apoptosis. Crit. Rev. Clin. Lab Sci. 42, 71–104.
Tuckermann, J.P., Kleiman, A., Moriggl, R., Spanbroek, R., Neumann, A., Illing, A.,
Clausen, B.E., Stride, B., Forster, I., Habenicht, A.J., Reichardt, H.M., Tronche, F.,
Schmid, W., Schutz, G., 2007. Macrophages and neutrophils are the targets for
immune suppression by glucocorticoids in contact allergy. J. Clin. Invest. 117,
1381–1390.
Umesono, K., Evans, R.M., 1989. Determinants of target gene speciﬁcity for
steroid/thyroid hormone receptors. Cell 57, 1139–1146.
r and C
v
v
v
V
V
W
W
W
W
W
W
W
W
W
W
W
W
WA.E. Coutinho, K.E. Chapman / Molecula
an der Laan, S., Sarabdjitsingh, R.A., Van Batenburg, M.F., Lachize, S.B., Li,
H., Dijkmans, T.F., Vreugdenhil, E., de Kloet, E.R., Meijer, O.C., 2008. Chro-
matin immunoprecipitation scanning identiﬁes glucocorticoid receptor binding
regions in the proximal promoter of a ubiquitously expressed glucocorticoid
target gene in brain. J. Neurochem. 106, 2515–2523.
an Staa, T.P., Leufkens, H.G.M., Abenhaim, L., Begaud, B., Zhang, B., Cooper, C., 2000.
Use of oral corticosteroids in the United Kingdom. QJM 93, 105–111.
an Tilborg, M.A., Lefstin, J.A., Kruiskamp, M., Teuben, J., Boelens, R., Yamamoto, K.R.,
Kaptein, R., 2000.Mutations in the glucocorticoid receptorDNA-binding domain
mimic an allosteric effect of DNA. J. Mol. Biol. 301, 947–958.
arga, G., Ehrchen, J., Tsianakas, A., Tenbrock, K., Rattenholl, A., Seeliger, S., Mack,
M., Roth, J., Sunderkoetter, C., 2008. Glucocorticoids induce an activated,
anti-inﬂammatory monocyte subset in mice that resembles myeloid-derived
suppressor cells. J. Leukoc. Biol. 84, 644–650.
egiopoulos, A., Herzig, S., 2007. Glucocorticoids, metabolism and metabolic dis-
eases. Mol. Cell Endocrinol. 275, 43–61.
ang, D.,Muller, N.,McPherson, K.G., Reichardt, H.M., 2006. Glucocorticoids engage
different signal transduction pathways to induce apoptosis in thymocytes and
mature T cells. J. Immunol. 176, 1695–1702.
ang, J.C., Derynck,M.K., Nonaka, D.F., Khodabakhsh, D.B., Haqq, C., Yamamoto, K.R.,
2004. Chromatin immunoprecipitation (ChIP) scanning identiﬁes primary glu-
cocorticoid receptor target genes. Proc. Natl. Acad. Sci. U.S.A. 101, 15603–15608.
ebster, J.I., Tonelli, L., Sternberg, E.M., 2002. Neuroendocrine regulation of immu-
nity. Annu. Rev. Immunol. 20, 125–163.
ei, L., MacDonald, T.M., Walker, B.R., 2004. Taking glucocorticoids by prescription
is associated with subsequent cardiovascular disease. Ann. Intern. Med. 141,
764–770.
hite, P.C., Rogoff, D., McMillan, D.R., Lavery, G.G., 2007. Hexose 6-phosphate
dehydrogenase (H6PD) and corticosteroid metabolism. Mol. Cell. Endocrinol.
265-266, 89–92.
horwood, C.B., Franklyn, J.A., Sheppard, M.C., Stewart, P.M., 1992. Tissue local-
isation of 11-hydroxysteroid dehydrogenase and its relationship to the
glucocorticoid receptor. J. Steroid Biochem. Mol. Biol. 41, 21–28.
hyte, M.K., Meagher, L.C., MacDermot, J., Haslett, C., 1993. Impairment of function
in aging neutrophils is associated with apoptosis. J. Immunol. 150, 5124–5134.
ilckens, T., 1995. Glucocorticoids and immune function: physiological relevance
and pathogenic potential of hormonal dysfunction. Trends Pharmacol. Sci. 16,
193–197.
ilckens, T., De Rijk, R., 1997. Glucocorticoids and immune function: unknown
dimensions and new frontiers. Immunol. Today 18, 418–424.
illiams, L.J.S., Lyons, V., MacLeod, I., Rajan, V., Darlington, G.J., Poli, V., Seckl,
J.R., Chapman, K.E., 2000. C/EBP regulates hepatic transcription of 11-
hydroxysteroid dehydrogenase type 1; a novel mechanism for cross talk
between the C/EBP and glucocorticoid signalling pathways. J. Biol. Chem. 275,
30232–30239.
issink, S., vanHeerde, E.C., vandder Burg, B., vander Saag, P.T., 1998. Adualmecha-
nism mediates repression of NF-B activity by glucocorticoids. Mol. Endocrinol.
12, 355–363.
u, J.J., Roth, R.J., Anderson, E.J., Hong, E.-G., Lee, M.-K., Choi, C.S., Neufer, P.D., Shul-
man, G.I., Kim, J.K., Bennett, A.M., 2006. Mice lacking MAP kinase phosphatase-1
have enhanced MAP kinase activity and resistance to diet-induced obesity. Cell
Metab. 4, 61–73.
ust, S., van den Brandt, J., Tischner, D., Kleiman, A., Tuckermann, J.P., Gold, R.,
Luhder, F., Reichardt, H.M., 2008. Peripheral T cells are the therapeutic targets
of glucocorticoids in experimental autoimmune encephalomyelitis. J. Immunol.
180, 8434–8443.ellular Endocrinology 335 (2011) 2–13 13
Yamada, K., Duong, D.T., Scott, D.K., Wang, J.-C., Granner, D.K., 1999. CCAAT/
enhancer-binding protein  is an accessory factor for the glucocorticoid
response from the cAMP response element in the rat phosphoenolpyruvate
carboxykinase gene promoter. J. Biol. Chem. 274, 5880–5887.
Yamamoto, K.R., 1985. Steroid receptor regulated transcription of speciﬁc genes and
gene networks. Ann. Rev. Genet. 19, 209–252.
Yang, H., Mammen, J., Wei, W., Menconi, M., Evenson, A., Fareed, M., Petkova, V.,
Hasselgren, P.O., 2005a. Expression and activity of C/EBP and  are upregulated
by dexamethasone in skeletal muscle. J. Cell. Physiol. 204, 219–226.
Yang, H., Menconi, M.J., Wei, W., Petkova, V., Hasselgren, P.O., 2005b. Dexametha-
sone upregulates the expression of the nuclear cofactor p300 and its interaction
with C/EBP in cultured myotubes. J. Cell. Biochem. 94, 1058–1067.
Yang, Y.H., Aeberli, D., Dacumos, A., Xue, J.R., Morand, E.F., 2009a. Annexin-1 reg-
ulates macrophage IL-6 and TNF via glucocorticoid-induced leucine zipper. J.
Immunol. 183, 1435–1445.
Yang, Y.H., Morand, E.F., Getting, S.J., Paul-Clark, M., Liu, D.L., Yona, S., Hannon, R.,
Buckingham, J.C., Perretti,M., Flower, R.J., 2004.Modulationof inﬂammation and
response to dexamethasone by Annexin 1 in antigen-induced arthritis. Arthritis
Rheum. 50, 976–984.
Yang, Z., Guo, C., Zhu, P., Li,W.,Myatt, L., Sun, K., 2007. Role of glucocorticoid receptor
and CCAAT/enhancer-binding protein- in the feed-forward induction of 11-
hydroxysteroid dehydrogenase type 1 expression by cortisol in human amnion
ﬁbroblasts. J. Endocrinol. 195, 241–253.
Yang, Z., Zhu, X., Guo, C., Sun, K., 2009b. Stimulation of 11-HSD1 expression by
IL-1 via a C/EBP binding site in human fetal lung ﬁbroblasts. Endocrine 36,
404–411.
Yangyen, H.F., Chambard, J.C., Sun, Y.L., Smeal, T., Schmidt, T.J., Drouin, J., Karin, M.,
1990. Transcriptional interference between c-Jun and the glucocorticoid recep-
tor: mutual inhibition of DNA binding due to direct protein-protein interaction.
Cell 62, 1205–1215.
Yeager,M.P., Guyre, P.M.,Munck, A.U., 2004. Glucocorticoid regulation of the inﬂam-
matory response to injury. Acta Anaesthesiol. Scand. 48, 799–813.
Yona, S., Buckingham, J.C., Perretti, M., Flower, R.J., 2004. Stimulus-speciﬁc defect in
the phagocytic pathways of annexin 1 null macrophages. Br. J. Pharmacol. 142,
890–898.
Yoshinaga, S.K., Yamamoto, K.R., 1991. Signaling and regulation by a mam-
malian glucocorticoid receptor in Drosophila cells. Mol. Endocrinol. 5, 844–
853.
Zbankova, S., Bryndova, J., Leden, P., Kment, M., Svec, A., Pacha, J., 2007. 11-
hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with
ulcerative colitis. J. Gastroenterol. Hepatol. 22, 1019–1023.
Zhang, J., Ge, R., Matte-Martone, C., Goodwin, J., Shlomchik, W.D., Mamula, M.J.,
Kooshkabadi, A., Hardy, M.P., Geller, D., 2009. Characterization of a novel gain
of function glucocorticoid receptor knock-in mouse. J. Biol. Chem. 284, 6249–
6259.
Zhang, T.Y., Daynes, R.A., 2007. Macrophages from 11-hydroxysteroid dehydroge-
nase type 1-deﬁcientmice exhibit an increased sensitivity to lipopolysaccharide
stimulation due to TGF--mediated up-regulation of SHIP1 expression. J.
Immunol. 179, 6325–6335.
Zhang, T.Y., Ding, X., Daynes, R.A., 2005. The expression of 11-hydroxysteroid
dehydrogenase type I by lymphocytes provides a novel means for intracrine
regulation of glucocorticoid activities. J. Immunol. 174, 879–889.
Zhao, Q., Wang, X., Nelin, L.D., Yao, Y., Matta, R., Manson, M.E., Baliga, R.S., Meng,
X., Smith, C.V., Bauer, J.A., Chang, C.H., Liu, Y., 2006. MAP kinase phosphatase 1
controls innate immune responses and suppresses endotoxic shock. J. Exp. Med.
203, 131–140.
